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Molecular Determinants of Residual Disease in Ovarian Cancer
Kshipra M. Gharpure
Advisory Professor: Anil K. Sood, M.D.
The standard treatment for high grade serous ovarian cancer is primary cytoreductive
surgery followed by adjuvant chemotherapy. Residual disease followed by surgery is
associated with adverse overall and progression-free survival as well as poor
response to adjuvant chemotherapy. Accurate identification of patients at high risk of
residual disease will help avoid unnecessary surgeries and help in triaging these
patients to neoadjuvant chemotherapy prior to interval surgical debulking. In this
study, we address this clinical issue by identifying and validating molecular biomarkers
that can predict the likelihood of residual disease in ovarian cancer patients. Using
publically available databases and microarray datasets, we identify FABP4 and
ADH1B as markers of residual disease since the high expression of these genes in
tumor samples is directly associated with the incidence of residual disease. We then
investigate the underlying biology of residual disease and further demonstrate that
FABP4 is functionally responsible for aggressive phenotype of ovarian cancer cells
that lead to residual disease in cancer patients. Using sophisticated bioinformatics
techniques, several in vitro and in vivo experiments and analysis of patient samples,
we explored upstream regulation of FABP4 and identified miR-409-3p as a key
regulator of FABP4 expression. We further discover hypoxia as a main tumor microenvironmental factor regulating miR-409-3p and FABP4 in ovarian cancer. Using
RPPA and DESI-MS imaging techniques, we explore the downstream pathways of

iv

FABP4 and discovered that FABP4 regulates several pathways associated with
metastasis as well as it affects several metabolites in ovarian cancer cells.
Collectively, our study provides the mechanistic understanding of residual disease
biology and identifies miR-409-3p and FABP4 as potential therapeutic targets for
ovarian cancer treatment.
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Chapter 1: Introduction
1.1 Residual disease in ovarian cancer
Primary cytoreduction followed by adjuvant chemotherapy is the standard
mode of treatment for ovarian cancer patients. Residual disease following the primary
debulking surgery has been associated with worse overall and progression-free
survival as well as poor response to adjuvant chemotherapy. Historically, surgeries
resulting in the residual tumor of size 2 cm or more were labeled as suboptimal;
whereas the one resulting in smaller tumors were regarded as optimal surgeries. The
goal of the primary debulking was to achieve optimal cytoreduction since the survival
rate was proven to be inversely proportional to the size of the residual tumor [1].
There were however differences in the definitions of ‘optimal debulking’. In
1975, a study of 102 patients of stage 2 and 3 concluded 1.5 cm to be the threshold.
Surgeries that left the patients with a residual tumor greater than 1.5 cm diameter were
called ‘suboptimal’ whereas others were called ‘optimal’. The study showed poor
survival for patients with residual disease diameter greater than 1.5 [1]. Later studies
by Chi et al. and Hoskins et al. (GOG 97), however concluded that patients with
residual disease less than 1cm had better survival than the ones with larger tumor
size [2, 3]. Other studies confirmed these observations and a threshold of 1 cm was
used to determine whether a surgery was optimal or suboptimal [4, 5]. Advances in
surgical techniques and postoperative care made aggressive cytoreduction more
feasible and complete resection of residual disease became achievable. Recent
studies thus focused on the survival differences between complete resection (no
residual disease, R0) and any visible residual disease (R0). They noticed that each
1

10% increase in extent of debulking resulted in 5.5% or 2-3 months of increase in
patient survival [6, 7]. GOG trials 104 and 172 further supported the data and
concluded that significant survival differences exist between patients with no visible
residual disease and patients with gross residual disease (< 0.5 cm or 0.5-2 cm) [8,
9]. Studies since then have identified complete cytoreduction as an independent
prognostic factor for overall survival with data showing the longest survival (86
months) for patients with no gross residual disease compared to 37-46 months of
survival for patients with 0.1-1cm and >1cm RD [10, 11]. An exploratory study of 3126
patients from 3 randomized trials by duBois et al. was one of the largest studies to
establish the importance of R0. The study concluded that the patients with R0 had
significantly better survival than patients with RD and there was no significant survival
difference between patients with RD 0.1-1cm or greater than 1 cm. The study also
showed the median recurrence time for patients with R0 was 15.5 months, whereas
recurrence was shorter for patients with RD 0.1-1cm or greater than 1cm [12].
Though complete resection is the ultimate goal of the surgeries, it should be
noted that even highly experienced gynecologic oncology surgeons end up leaving
residual disease. Studies have shown that approximately two-thirds of the patients
with advanced-stage ovarian cancer get residual disease after the PDS [13]. This can
happen due to the presence of numerous, dense nodules that simply can’t be
removed, distant tumor metastasis, location of tumor near critical organs (e.g., porta
hepatis), extensive mesenteric involvement etc. Thus, not only surgical skills but tumor
biology also plays a crucial role in residual disease pathology.
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1.1.1 Neoadjuvant chemotherapy vs primary debulking
While complete cytoreduction is potentially achievable at most in 30% of the
cases using aggressive surgical procedures; not all patients can tolerate such an
approach. Women with advanced stage disease, bulky tumor, widespread metastasis
or women who are very weak and sick to undergo any surgery may not be good
candidates for extreme surgical efforts. Neoadjuvant chemotherapy is thus being
suggested as an alternative to primary debulking surgery. The idea is to reduce tumor
burden using neoadjuvant chemotherapy and thus improve the chances of achieving
R0 at the interval surgery.
A randomized clinical trial of 718 patients was conducted by EORTC (European
Organisation

for

Research

and

Treatment

of

Cancer)

and

NCIC

(National Cancer Institute of Canada). The patients were randomly assigned to
primary debulking surgery (PDS) or to neoadjuvant chemotherapy (NACT) followed
by interval debulking surgery (IDS). Although progression-free survival (PFS) and
overall survival (OS) were similar in both the groups, the rate of achieving optimal
cytoreduction was higher (80.6%) in patients after NACT-IDS than in the patients who
received PDS (41.6%). Furthermore, patients who underwent NACT and IDS had
improved quality of life as measured by lesser postoperative complications and
infections compared to the patients who received PDS [14]. Results from another
multicenter phase 3 clinical trial of patients with advanced stage disease showed that
NACT resulted in higher chances of optimal debulking with similar OS and PFS.
Several retrospective studies and meta-analyses have so far suggested that NACT is
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equivalent to PDS in terms of survival and can be a better treatment option for patients
in which optimal cytoreduction is not possible following PDS [15-18].
Although neoadjuvant chemotherapy is a potentially feasible alternative, there
can be risks of side effects, drug resistance and refractory diseases that are
associated with NACT. Further studies are thus essential before NACT can be
included in the standard of care [17]. On the other hand, patients who are very sick or
have tumor burden that cannot be optimally debulked, benefit little from the aggressive
surgery. They might in fact suffer from the morbidities associated with such an
approach. It is therefore extremely important to carefully determine whether a given
patient will benefit from NACT or PDS.

1.1.2 Predictors of residual disease
To determine if a patient will or will not have a suboptimal resection or residual
disease, various predictive tools have been developed and tested.
Given the importance of CA-125 as a marker for advanced stage ovarian
cancer, many studies have evaluated the ability of CA-125 as a predictive marker for
optimal cytoreduction [19-21]. Optimal debulking was achieved in 73% of the cases
when CA-125 levels were lower than 500 U/ml, conversely when CA-125 levels were
higher than 500U/ml, only 22% of the cases resulted in optimal cytoreduction [20].
Some studies also evaluated the changes in serum CA-125 after NACT and
concluded that patients with CA-125 levels < 100 U/ml are likely to achieve R0 status
after IDS than patients with higher CA-125 levels [22]. However, contradicting results
from additional studies suggested that levels of CA-125 cannot be used as a reliable
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predictor for suboptimal cytoreduction [23-26]. Another such serum marker (HE4) was
also evaluated and retrospective analysis indicated HE4 levels of 264pmol/L and
ascites volume < 500mL can predict optimal cytoreduction with 100% sensitivity and
89.5% specificity [27]. The studies however lack external validations.
Computed Tomography (CT) imaging is the most commonly studied modality
to predict residual disease in patients. Several studies have tried to build prediction
models based on the CT scans of ovarian tumors. In a retrospective study of 118
patients, Kim et al. identified extension of omental disease to stomach and spleen,
and metastasis at inguinal and pelvic lymph nodes observed in CT scans as predictive
markers for suboptimal cytoreduction in ovarian cancer patients [28]. Another study
reported CT findings of attachment of the omentum to the spleen and tumor burden
of greater than 2 cm on the diaphragm, liver surface, or parenchyma, pleura,
mesentery, gallbladder fossa, or suprarenal para-aortic nodes to be predictors of
residual disease with a positive predictive value of 67% and negative predictive value
of 96% [29]. Similar retrospective studies by Bristow et al. and Dowdy et al. reported
large volume of ascites and CT scan showing peritoneal thickening, omentum
extensions and mesenteric tumor burden as predictors of suboptimal cytoreduction
[30, 31]. A prospective, multicenter, non-randomized trial of advanced stage ovarian
cancer patients was conducted to explore the combination of CA-125 and CT scan as
a predictive tool for suboptimal primary debulking surgery. Advanced stage, CA-125>
500U/ml and metastasis at retroperitoneal lymph node, small bowel mesentery,
superior mesenteric artery, perisplenic area, lesser sac and small bowel thickening
were found to be indicators of suboptimal surgery. A predictive model using these
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criteria had an accuracy of 0.758 [32]. In another retrospective study, Janco et al.,
analyzed data from 279 patients and built a predictive model based on age, Eastern
Cooperative Oncology Group performance status (ECOG PS), American Society of
Anesthesiologists (ASA) score, thrombocytosis, CA-125 levels, albumin levels and CT
images of lymphadenopathy (LP), large-volume ascites, diffuse peritoneal thickening
(DPT), omental cake, and spleen or liver involvement. ECOG PS, DPT, and LP were
found to be markers of suboptimal surgery with c index value of 0.685[33].
Although studies have indicated that CT-based predictive models of residual
disease are promising, they have not been extensively validated. Moreover, the
predictive ability of CT scans depend largely on radiological skills, surgical techniques
and surgeon’s and radiologist’s view and assessments of the scans [13, 34].
Since the previously described predictive models had limited success,
laparoscopic methods were explored to assess the resectability of tumor burden. A
pilot study comparing the predictive ability of laparoscopy and laparotomy revealed
the overall accuracy of laparoscopy in predictive residual disease as 97%. In no cases,
the prediction of suboptimal disease changed by the laparotomy performed later. Thus
laparoscopy was proved to be as reliable as laparotomy while avoiding unnecessary
cytoreduction and morbidity associated with laparotomy [35]. Fagotti et al. then
developed a quantitative prediction model based on the laparoscopic findings of tumor
metastasis. Table 1 describes the scoring schema formulated by Fagotti et al. to
calculate predictive index value (PIV) for each patient [13, 36]. A score of 8 or above
was said to predict the likelihood of suboptimal cytoreduction. The positive predictive
value for the technique was 100% whereas the negative predictive value was 70%
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[36]. This method of a score-based predictions of RD was evaluated by at least two
other studies- A study by Angioli et al. reported that 96% of the patients predicted to
have R0 resection, had optimal debulking [37]. Brun et al. reported that the specificity
and positive predictive values for the Fagotti score were 89% and 89% respectively
while the sensitivity and negative predictive values were 46% and 44% [38].

Table 1 A scoring schema developed by Fagotti et al. to calculate predictive index
value (Taken with permission from the copyright holder, Nick, A.M., R.L. Coleman,
P.T. Ramirez, and A.K. Sood, A framework for a personalized surgical approach to
ovarian cancer. Nat Rev Clin Oncol, 2015. 12(4): p. 239-45.)

7

To assess the accuracy of the laparoscopic measurements, Fagotti et al.
conducted a multicenter, prospective trial (Olympia-MITO13) of 120 patients. Apart
from mesenteric retraction, all other variables reached an accuracy rate of 80% or
more thus establishing the reproducibility of laparoscopic scoring [39]. The Fagotti
score was again used in the SCORPION trial where primary debulking and
neoadjuvant chemotherapy followed by IDS were compared. Patients with scores
between 8-12 were randomly triaged to receive either neoadjuvant chemotherapy or
PDS. The primary results of the trial were promising. The study reported that rates of
complete debulking (R0) were similar in both the groups and quality of life scores were
better for the patients who received neoadjuvant chemotherapy [40]. The predictive
index scoring is also a part of M.D. Anderson algorithm which was developed as a
part of the women’s cancer moon shot program. Figure 1 explains the algorithm. As a
part of quality improvement initiative, a laparoscopic assessment is conducted for
each patient and the scoring is done by two surgeons to ensure an agreement about
tumor resectability. An additional opinion is considered if necessary. After this careful
assessment of disease distribution by two or more surgeons, a patient is triaged either
for PDS or NACT followed by IDS depending upon the scores. Thus PDS is
recommended for patients only when R0 resection is potentially achievable. Novel
therapeutic agents are offered to the patients after the laparoscopy and prior to the
PDS (window of opportunity). Preliminary results have indicated increased rates of
complete resection (20% pre-implementation versus 84% post-implementation) and
improved chances of R0 after neoadjuvant chemotherapy (65% pre-implementation
versus 100% post-implementation) [13].

8

Figure 1 A schema for patients treated on the Anderson algorithm
(Taken with permission from the copyright holder, Nick, A.M., R.L. Coleman, P.T.
Ramirez, and A.K. Sood, A framework for a personalized surgical approach to ovarian
cancer. Nat Rev Clin Oncol, 2015. 12(4): p. 239-45.)

Residual disease could be a result of lack of surgical skills or location of nodules
near critical organs or it could be because of invasive tumor biology. Considering that
residual disease could be a consequence of biological characteristics of tumors, we
hypothesized that tumor tissue based markers might be able to predict the likelihood
of residual disease with high sensitivity. If a certain numeric threshold is established
for the gene expression, then this method is essentially free of any subjective
assessment seen in CT scans etc. Some studies have tried to develop molecular
predictors for residual disease. They do however have certain limitations. Using
stringent inclusion, exclusion criteria for tumor samples and validation studies, we
discovered molecular biomarkers (FABP4 and ADH1B) to predict residual disease in
ovarian cancer.
1.2 FABP4 (Fatty acid binding protein 4) and its biological functions
1.2.1 Role of FABP4 in various cell types
9

The FABP4 gene encodes fatty acid binding protein 4. It belongs to a family of
fatty acid binding proteins that are intracellular lipid chaperons. They can reversibly
bind to hydrophobic ligands such as fatty acids, eicosanoids and other lipids. The
molecular weight of FABPs is 14-15 kDa and they share 20-70% sequence identity
between different isoforms. Fatty acid binding protein 4 is also knowns as A-FABP4
or ap2 since it was first detected in adipocytes. Since then studies have shown that
FABP4 is also present in macrophages, endothelial cells, dendritic cells and tumor
cells [41-43]. In all these various cell types; FABP4 plays crucial roles in various
cellular functions.
As a lipid chaperon, FABPs can transport fatty acids and lipids to various cell
organelles. For example, it can transport lipids and fatty acids to mitochondria or
peroxisome for oxidation, to the nucleus for lipid-mediated transcriptional regulation.
The cells can secrete FABP4 and thus lipids outside the cells as a means of paracrine
communication or it can store it in cytosol to regulate enzymatic activity. FABP4 can
also send lipids to endoplasmic reticulum for membrane synthesis and signaling or it
can transport fatty acids, lipids to lipid droplets for storage [44].
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Figure 2 Functions of FABP in the cells [44]
(Taken with permission from the copyright holder. Furuhashi, M. and G.S. Hotamisligil,
Fatty acid-binding proteins: role in metabolic diseases and potential as drug targets.
Nat Rev Drug Discov, 2008. 7(6): p. 489-503.)
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Figure 3 Role of FABP4 in lipid metabolism and inflammation[45]
(Taken with permission from the copyright holder. Hotamisligil, G.S. and D.A.
Bernlohr, Metabolic functions of FABPs--mechanisms and therapeutic implications.
Nat Rev Endocrinol, 2015. 11(10): p. 592-605.)

FABP4 is known to be upregulated during differentiation of preadipocytes into
adipocytes [46] and is known to regulate de novo lipogenesis [47]. It suppresses
adipose tissue lipogenesis and increases lipolysis. It is also known to regulate
eicosanoids, JAK2 and CD36 thus influencing various pathways related to
inflammation. Increased levels of secreted FABP4 have been linked with obesity.
FABP4 regulated lipid signaling has been known to influence glucose tolerance and
insulin sensitivity.
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Figure 4 Functions of circulating FABP4[45]
(Taken with permission from the copyright holder. Hotamisligil, G.S. and D.A.
Bernlohr, Metabolic functions of FABPs--mechanisms and therapeutic implications.
Nat Rev Endocrinol, 2015. 11(10): p. 592-605.)

FABP4 present in lung endothelial cells has been implicated in VEGF-induced
airway angiogenesis and inflammation. Studies have thus shown that FABP4 plays a
key role in vascular remodeling of airways and thus pathogenesis of asthma [48].
FABP4 is also expressed in differentiated and activated macrophages [44]. It
regulates cholesterol accumulation in macrophages and also modulates inflammatory
responses. It regulates several cytokines and pro-inflammatory enzymes such as
tumor necrosis factor (TNF-1α), interleukin 1-β (IL1β), monocyte chemoattractant
13

protein 1 (MCP1), nitric oxide synthase (iNOS) and cyclooxygenase 2 (COX2). FABP4
has also been shown to regulate NF-kB and IKK (inhibitor of kappa kinase) and thus
controls inflammatory and cytokine responses [49]. FABP4 also regulates foam cell
formation and thus contributes to atherosclerosis [49, 50].
1.2.2 Role of FABP4 in cancer progression
Recent studies have highlighted the importance of FABP4 in tumor
progression. In HUVEC cells, FABP4 regulates several pathways involving P38,
eNOS, stem-cell factor (SCF)/c-kit and controls endothelial cell proliferation, migration
and sprouting. In ovarian cancer, FABP4 has been shown to increase angiogenesis
thus contributing to tumor progression [43]. In endothelial cells, inhibition of FABP4
increased reactive oxygen species and decreased angiogenesis. Knockdown of
FABP4 in vivo using siRNA treatment, reduced proliferation (ki67), increased
apoptosis (CC3) and reduced number of endothelial vessels (CD31) and thus had
tumor inhibitory effects [51].
In ovarian cancer, FABP4 is known to play a key role in the interaction between
cancer cell and adipocytes. Co-culture of adipocytes and cancer cells resulted in
FABP4 mediated increased lipid content in cancer cells. Adipocytes thus provided
lipids and induced β oxidation pathway in cancer cells, therefore promoting tumor
progression by providing energy to cancer cells. The study further showed that
knockout mouse model of FABP4 had lesser metastasis than the control mice [52]. In
oral squamous cell carcinoma, FABP4 is predominantly expressed in tumor tissues
compared to the non-tumorous tissues. Moreover, knockdown of FABP4 in SCC
cancer cell line resulted in decreased cell proliferation possibly by inhibition of
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phosphorylation of MAPK [53]. In breast cancer cells, treatment with exogenous
FABP4 led to increased cell proliferation by inducing AKT-MAPK signaling cascade.
Increase in FABP4 also led to an increase in the expression of fatty acid transport
proteins in these cells which can also leads to increasing proliferation [54].
Our study focuses on FABP4 specifically present in the ovarian cancer cells
and how it induces aggressive and infiltrative phenotype in the cells which ultimately
results in residual disease.
1.3 Desorption electrospray ionization mass spectrometry
Since some of the proteins that were significantly altered in our RPPA analysis
are also known to influence metabolic pathways and most importantly FABP4 is a fatty
acid binding protein known to be involved in fatty acid oxidation pathways, we decided
to investigate whether FABP4 affects the metabolic profile of ovarian cancer cell.
Ovarian cancer metabolomics have been studied previously. Studies revealing
glutamine dependency of cancer cells, importance of n-acetylaspartate pathway,
amplification of USP13 or higher expression of fatty acid synthase; have all
established the importance of metabolic changes occurring in cancer cells[55-58].
However, the studies do not provide spatial resolution of the metabolites. Without this
information, it is difficult to pinpoint the exact compartment of the tumor (cancer cells
or stroma) where the changes are occurring and hence it is difficult to fully
comprehend the dynamics of these changes. Imaging techniques coupled with MS
spectrometry, not only identify molecules or metabolites in a given sample but also
provide information about their spatial distribution. DESI-MS imaging is one such
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technique particularly used to analyze metabolites with low m/z values, such as lipids
[59].
DESI-MS imaging has been used to analyze tissue extracts or plants or animal
tissues [60-64]. Briefly, for the tissue analysis, a section of approximately 5-25 µm
thickness is used. Then, a spray of solvents is directed onto the sample. When the
droplets hit the tissue section, the analytes present in that area get dissolved in the
solvent. A continuous spray of the solvent helps to generate secondary microdroplets
containing the analytes that are then delivered to the mass spectrometry through an
extended heated capillary[65]. Tandem MS is then used to identify the analytes. An
image showing spatial distribution can then be made for each analyte. The most
commonly used solvent system for DESI-MS imaging is a mixture of water and
methanol or acetonitrile in combination with an acid modifier [61]. The composition of
the solvent used for the analysis is critical since it can affect desorption and ionization
of the molecules. The polarity of the solvent system also has an impact on the signals
obtained from the species and can be adjusted to specifically focus on certain species
[66, 67].
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Figure 5 DESI-MS imaging methodology [68]
(Taken with permission form the copyright holder. Takats, Z., J.M. Wiseman, B.
Gologan, and R.G. Cooks, Mass spectrometry sampling under ambient conditions
with desorption electrospray ionization. Science, 2004. 306(5695): p. 471-3.)
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Since the technique does not require any staining or labelling procedures, the
tissue morphology is maintained during the analysis [65]. This allows the images
constructed from the MS data, to be directly compared with the H&E images of the
tissue sections. Thus, it also helps to select the data from specific areas of the tissue
sections, if needed. Figure 6 shows how DESI-MS images are analyzed along with
H&E sections to know locations of a metabolite’s signals.

Figure 6 Example of DESI-MS images and comparison with H&E [69]
(Taken with permission from the copyright holder Zhang, J., W. Yu, S.W. Ryu, J. Lin,
G. Buentello, R. Tibshirani, J. Suliburk, and L.S. Eberlin, Cardiolipins Are Biomarkers
of Mitochondria-Rich Thyroid Oncocytic Tumors. Cancer Res, 2016. 76(22): p. 65886597)
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DESI-MS imaging has been mainly used to identify lipids present in the
biological specimens. In case of spinal cord injury, it has been used to explore timedependent chemical changes in the tissue and associate lipidomic profiles with the
injury [70]. Sequential analysis of 2D images collected from DESI-MS has been used
to construct 3D images of a mouse brain thus allowing to associate specific molecular
moieties with the substructures of brain [71]. Recent studies have focused on using
DESI-MS imaging as a diagnostic tool to differentiate between normal and cancerous
tissues. For example, in bladder cancer, a study of patient tissue samples revealed
that certain fatty acids, glycerophosphoinositols (PI) and glycerophosphoserines (PS)
are elevated in tumors compared to adjacent normal tissue [72, 73]. DESI-MS analysis
of prostate cancer tissues was also able to differentiate between cancerous and
normal sections based on cholesterol sulfate expression [74]. Similar studies in
glioblastoma, seminoma tissues and ovarian cancer have been conducted [75, 76]. In
all these studies, DESI-MS imaging was able to provide a visual distinction between
cancerous lesions and normal tissue section of a given specimen. Current work in the
field is focused on using DESI-MS for more complex classifications such as tumor
grading, differentiating between molecular subtypes of a cancer etc.

19

A comprehensive study of the determinants of residual disease is an unmet
need in the field of ovarian cancer. In this study, we first aimed to identify molecular
biomarkers that can predict the likelihood of residual disease with high sensitivity and
selectivity. After discovering FABP4 as a biomarker for residual disease, we studied
the upstream mechanism that leads to its upregulation in ovarian cancer. We then
investigated the pathways regulated by FABP4 that eventually lead to residual disease
in ovarian cancer.
Specific aims and hypothesis:
Aim 1: To identify a gene signature that will predict the residual disease status in
ovarian cancer patients.
Hypothesis: A gene signature predictive of residual disease status can be identified
through integrative analysis of patient database
Rationale: The standard treatment for ovarian cancer is to surgically remove as much
tumor as possible, followed by chemotherapy. Recent reports suggest that patients
most likely to benefit from surgery upfront are those with complete resection of disease
(R0), which is among the strongest predictors of overall survival. The rates of R0
resection are approximately 30%. Unfortunately, all patients are currently subjected
to a large incision for surgery when only 30% will have R0 resection and the remaining
would ideally be treated with neoadjuvant chemotherapy. There are no reliable
methods (e.g., imaging, biomarkers, etc.) that can accurately predict whether a given
patient will have R0 resection at surgery. We therefore aim to identify molecular
predictors of residual disease to allow reliable prediction of those most likely to benefit
from surgery (i.e., achieve R0 resection).

20

Aim 2: To identify the mechanisms by which FABP4 is up regulated in ovarian cancer
Hypothesis: Decreased miRNA levels lead to elevated expression of FABP4 in
ovarian cancer cells.
Rationale: High expression of FABP4 was found to correlate with high likelihood of
residual disease. Analysis of TCGA data revealed there is no correlation between
copy number and high FABP4 expression. After screening various microenvironmental factors, hypoxia seems to be the dominant factor related to
upregulation of FABP4 in ovarian cancer cell lines. Through our in silico analysis, we
discovered several miRNAs predicted to bind to 3’UTR of FABP4. Hence we propose
that a miRNA is the main regulator of FABP4 in ovarian cancer and is the reason of
its high expression in high grade serous ovarian tumors.

Aim 3: To determine the biological consequences of increased FABP4 expression on
ovarian cancer growth and metastasis and investigate the underlying mechanisms.
Hypothesis: FABP4 promotes ovarian cancer metastasis by regulating key proteins
and metabolites in cancer cells.
Rationale: One of the reasons that tumors cannot be resected is that they are widely
disseminated or they are infiltrated into normal organs. Our preliminary results show
that ectopic FABP4 promotes migration and invasion of cancer cells and silencing
FABP4 inhibits these processes. We hence believe that higher expression of FABP4
makes the cancer cells more infiltrative and metastatic, leading to residual disease.
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Chapter 2: Methods
Data for exploratory studies
For biomarker discovery, we used 2 large publicly available Affymetrix
microarray datasets involving patients with HGSOCs and providing associated clinical
information, including residual disease status. The first of these was the ovarian
cancer cohort from The Cancer Genome Atlas [77]. We downloaded CEL files (level
1 data) for the ovarian samples (Affymetrix HT HG-U133A arrays, n = 598) on
September 2, 2012; these represent the TCGA update that was current as of June 24,
2011 (revision 1007). We downloaded the associated clinical data (n = 576) on
September 14, 2012. We excluded samples if they were from recurrent tumor, omental
tumor, or normal tissue. When there were multiple primary tumor samples per patient,
we retained data from just one sample. We also excluded cases if there was no
information about residual disease status, if the tumor was not high grade, or if the
patient received neoadjuvant chemotherapy. The second dataset was from the study
of Tothill and colleagues [78]. We downloaded CEL files (Affymetrix U133+2
arrays, n = 285) and clinical data from the Gene Expression Omnibus (GSE9891) on
September 13, 2012. We excluded cases from this dataset if tumor samples were low
grade, of low malignant potential, non-serous histology, or non-ovarian or peritoneal
origin. Cases were also excluded if the patient received neoadjuvant chemotherapy
or if residual disease status was not provided. Accordingly, biomarker discovery was
performed using only data from primary tumors of chemotherapy naïve patients with
HGSOC.
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For each of the datasets described above, we quantified expression at the
probeset level with R statistical software (version 2.15.1) using the robust multi-array
average procedure as implemented in the subroutine justRMA in the R “affy” package
(version 1.34.0). We only considered probesets common to the array platforms used
in the first 2 datasets. Except for the 4 samples marked for exclusion by TCGA, our
sample filtrations described above were performed subsequent to the quantification
step.

Validation studies
Following identification of candidate genes having a wide dynamic range and
with high expression levels associated with high risk of residual disease in exploratory
analyses, we performed validation studies in an independent cohort. Following
Institutional Review Board approval, we obtained primary ovarian tumor samples from
archived surgical material at The University of Texas MD Anderson Cancer Center
(Houston, TX; n = 84) and the Pacific Ovarian Cancer Research Consortium at the
Fred Hutchinson Cancer Research Center (Seattle, WA; n = 55). We also included 41
samples of omental tumor tissue from MD Anderson for comparison. All samples were
selected from chemotherapy naïve tumors. Information about residual disease status
in the validation cohort was extracted from patient medical records by clinical
members of the team and was scored as R0 versus any residual disease. This
information was kept blinded from all other team members until after predictions were
made concerning identification of a subset of patients at high risk for residual disease.
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These predictions were made on the basis of expression levels of a candidate gene
of interest relative to 18S, assayed using qRT-PCR.

Exploratory data analyses.
We used 2-sample t tests to compare expression levels by residual disease
status (R0 vs. any residual disease) in the TCGA and Tothill datasets, separately. We
analyzed the resulting collections of nominal P values to identify probesets significant
at a 10% or 5% false discovery rate (FDR) in each data set separately. We selected
probesets meeting the specified criterion in both subsets. We produced density plots
for these probesets, as well as heatmaps using hierarchical clustering, to illustrate
patterns of expression. We examined the resulting plots to identify probesets with (i)
wide dynamic range and (ii) high levels of expression associated with particularly high
incidence of residual disease. We examined similar plots for the selected probesets
in the Bonome and CCLE datasets to see whether the qualitative expression patterns
were also observed there.

Selecting a sample size and prediction threshold for the validation study.
Following identification of genes for which high expression levels were
associated with high risk of residual disease, we wished to select an a priori decision
threshold for “calling” a patient in the validation cohort to be at high risk of residual
disease based on elevated biomarker expression measured by qRT-PCR. Patients
with expression of a candidate biomarker gene above the selected threshold would
be in the predicted high-risk group for residual disease. To select a decision threshold,
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we first computed the positive predictive values (PPV) in the TCGA and Tothill
datasets at thresholds defined by varying quantiles of biomarker expression. We
assumed that similar PPVs would apply to the validation cohort and performed
numerical simulations to determine a decision threshold at which we would be
maximally powered to detect a difference in incidence of residual disease in the
validation set. We chose a threshold with an estimated power of at least 80% to detect
a difference in incidence of residual disease significant at P < 0.05 using a 1-sided
Fisher exact test. We used similar simulations for our initial sample size computations
before collecting the validation set.

Statistical assessment of success.
We constructed a 2 × 2 table showing our calls (high risk of residual disease
vs. lower risk of residual disease) compared with actual surgical outcomes (residual
disease vs. R0) in the validation cohort. We used a 1-sided Fisher exact test to test
the null hypothesis of equivalent rates of residual disease in the 2 groups against the
alternative of increased incidence of residual disease in the predicted high-risk group.

Quantitative RT-PCR analysis.
Total RNA was extracted from the tumor tissues using the TRIzol® extraction
method. RNA was then quantified using a nanodrop method and the 260/280 ratios
were also checked to determine quality. RNA (1µg/sample) was reverse transcribed
into cDNA using the Verso cDNA kit (Thermo Scientific, West Palm Beach, FL)
according to the manufacturer's protocol.
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qRT-PCR was performed on a 7500 PCR system (Applied Biosystems, Warrington,
UK) using 1µL of cDNA for each sample. SYBR green (Applied Biosystems) was used
to detect the products and 20pmoles of primer were used for the reaction. All reactions
were carried out with 20µL of reaction mix and were performed in triplicate. We used
the following primers: For FABP4, 5'-TGATGATCATGTTAGGTTTGGC-3' (forward)
and

5'-TGGAAACTTGTCTCCAGTGAA-3'

(reverse).

For ADH1B,

5'-

AGGGTAGAGGAGGCTGAAGA-3' (forward), 5'-ACCTGCTTCACTCTGGGAAA-3'
(reverse). The PCR reactions were run under the following conditions: 50°C for 2
minutes, 95°C for 15 minutes, followed by 40 cycles at 95°C for 1 minute each. All
reactions were analyzed with the 7500 Applied Biosystems PCR software (v.2.0.5).
The cycle threshold (Ct) values of the target genes were initially normalized to the Ct
values of 18S rRNA and melt curves were checked to determine the specificity of the
reactions.

Cell line maintenance and siRNA and miRNA transfection
All cancer cell lines were maintained at 37°C and 5% CO2 in culture with RPMI1640 or Dulbecco’s modified Eagle medium supplemented with 15% fetal bovine
serum and 0.1% gentamicin sulfate (Gemini Bio-Products, Calabasas, CA, USA). The
cell lines were obtained from American Type Culture Collection and were routinely
tested for absence of Mycoplasma and were validated using Short Tandem Repeat
DNA fingerprinting. All the in vitro experiments were performed at 60-80% cell
confluence.
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All siRNA transfections were conducted using Lipofectamine as a transfecting
agent. SiRNA concentration of 100 nM was used, and the ratio of Lipofectamine (Life
Technologies, Carlsbad, CA, USA) to a specific siRNA was 3:1. The cells were treated
with siRNAs for 4 hrs in serum-free media before incubation in complete media for the
specified time frame. For miRNA transfections (mimic and anti-miRNA), RNAiMAX
(Life Technologies, Carlsbad, CA, USA was used as a transfection agent, and the
ratio of RNAiMAX to a specific miRNA was 2:1. The concentration of miRNA-mimic or
anti-miR was 40 nM concentration and the transfections were conducted in serumfree conditions. After 4 hrs, the cells were incubated in complete media for the
specified time frame. The sequences for siRNAs and miRNAs are listed in Table 2.

In vivo models
Female athymic nude mice were purchased from Taconic Farms (Hudson, NY)
and housed in pathogen-free conditions. The mice were cared for according to the
guidelines of the American Association for Accreditation for Laboratory Animal Care
International and the US Public Health Service Policy on Humane Care and Use of
Laboratory Animals. All in vivo experiments and protocols were approved by MD
Anderson’s Institutional Animal Care and Use Committee.
For all in vivo experiments, cells were trypsinized at 60-80% confluence,
neutralized with FBS-containing media and centrifuged at 1200 rotations per minute
at 4°C for 6 minutes. The cells were then washed with phosphate-buffered saline
(PBS) and reconstituted in Hank’s balanced salt solution (HBSS, Gibco, Carlsbad,
CA, USA) to the desired concentration (1 × 106 cells/mouse in 50 µl for A2780 cells,
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8 × 105 cells/mouse in 50 µl for luciferase-labelled HeyA8 MDR cells, 1 × 106
cells/mouse in 50 µl for luciferase-labelled Ovcar 5 cells). Mice were anesthetized with
ketamine, and an incision was made above the left ovary. The cells were directly
injected into the ovary using a 1-ml tuberculin syringe with a 30-gauge needle. The
incision was then closed using surgical clips and sutured to ensure complete closure
of the surgery site. The mice were returned to cages until full recovery. Mice were
given sustained-release buprenorphine subcutaneously for pain management, and
the clips were removed after a week when the incision was completely healed.
No therapeutic intervention was conducted in the experiment in which FABP4overexpressing cells were injected. For all therapeutic experiments, a siRNA or
miRNA dose of 200 μg/kg was used, and the treatments were started 1 week after cell
injections. The mice were divided into two groups: control and treatment, 10
mice/group. Mice in the control group received control siRNA or control miRNA
incorporated into neutral DOPC liposomes. Mice in the treatment group received
FABP4 siRNA or a miR-409-3p mimic incorporated into DOPC liposomes. The doses
were given twice weekly intraperitoneally. The mice were monitored daily for any toxic
effects. Luciferase imaging was conducted to observe the effect of treatments on the
metastasis as described previously [79]. Briefly, Imaging and data acquisition were
performed with the IVIS Spectrum in vivo imaging system coupled to Living Image
Software (Xenogen). The mice were first anesthetized in an acrylic chamber with a
mixture of 1% isoflurane. They were then injected intraperitoneally with luciferin
potassium salt (15 mg/ml) in PBS at a dose of 150 mg/kg body weight. A digital
grayscale image was initially acquired, which was then overlaid with a pseudocolor
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image representing the spatial distribution of detected photons emerging from active
luciferase present within the animal. Signal intensity was expressed as a sum of all
photons detected per second. Once a mouse in any group became moribund, all mice
were euthanized. Mouse weight, tumor weight, number of nodules and locations of
metastasis were recorded. Tumor tissues were then frozen in optimal cutting
temperature media, fixed in formalin for paraffin embedding or snap-frozen.

Liposomal nanoparticle preparation
Incorporation of siRNA or miRNA into DOPC liposomes was achieved as
previously described [80]. Briefly, DOPC and siRNA or miRNA were mixed at a ratio
of 1:10 (w/w) in the presence of tertiary butanol. Tween 20 was added to the mixture
at a ratio of 1:19. The mixture was vortexed and frozen in an acetone/dry ice bath and
lyophilized. The lyophilized preparations were hydrated with PBS at room temperature
to a concentration of 200 µg of siRNA or miRNA/kg per injection per mouse.

MiRNA-mRNA expression association in TCGA OV samples
TCGA cases were included if the patients had high-grade disease and no
history of pre-treatment. TCGA gene expression quantification were produced using
justRMA applied to the CEL files from TCGA (Affymetrix HT HG-U133A arrays, n =
598) ([4]). TCGA miRNA microarray level 3 data (Agilent 8 x 15K Human miRNAspecific microarray) was obtained from the Data Access Matrix. Data was available
for 799 miRNAs. There were 541 samples meetings the inclusion criteria who had
both gene expression and miR data available. The association between each probe
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for the gene of interest and each available miRNA was assessed using the Maximal
Information Coefficient (MIC) computed using MINE software of Reshef et al. [81].

MiRNA-mRNA Interactions
We

retrieved

miRNA-target

interaction

information

(http://www.umm.uni-heidelberg.de/apps/zmf/mirwalk/)

that

from

hosts

miRWalk2.0
miRNA-target

predictions from twelve programs. We selected the cases predicted by at least seven
algorithms (half of the total number of programs checked+1). The interaction between
miR-409-3p and FABP4 (NM_001442) (3’ UTR) was predicted by nine programs
(miRWalk, Microt4, miRanda, miRMap, miRNAMap, PITA, RNA22, RNAhybrid,
Targetscan). We used Perl to sort the information available and Latex to present the
sites most probably to interact.

Luciferase reporter assays, and FABP4 3′UTR site mutagenesis
Luciferase assays were conducted as described previously [82]. Briefly, a
GoClone pLightSwitch luciferase reporter for the 3’UTR of FABP4 was purchased
from Switchgear Genomics (Menlo Park, CA, USA).
HeyA8 MDR cells were transfected with control miRNA or miR-409-3p mimic
(100 nM; Life Technologies, Carlsbad, CA, USA) with the help of FuGENE HD
transfection agent. The cells were also transfected with 3’UTR reporter constructs and
Cypridina TK controls (pTK-Cluc). After 24 h, the LightSwitch Dual Luciferase assay
kit was used and the luciferase signal was measured using a microplate luminometer,
as per the manufacturer’s guidelines (Biotek, Winooski, VT, USA). Luciferase activity
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was normalized using the Cypridina TK control, and an empty 3’UTR construct was
used as a negative control. The ratios were then normalized to the scrambled control
miRNA. Mutant FABP4 3’UTR was created for the predicted binding site mentioned in
Figure 21 using a QuickChange lightning multi-site-directed mutagenesis kit (Agilent
Technologies, Santa Clara, CA, USA) using the primers mentioned in Table 2. The
mutation was then confirmed using Sanger DNA sequencing before the mutant
FABP4 3’UTR was used for the luciferase assay.

Immunoblotting
Protein lysates from tumor tissues or cultured cells were prepared using
modified RIPA buffer containing proteinase and phosphatase inhibitors. Protein
concentrations were determined using the BCA protein assay reagent kit (Pierce
Biotechnology, Rockford, IL, USA). Lysates were loaded and separated on SDSpolyacrylamide gels. The proteins were then transferred to a nitrocellulose membrane
using a semidry electrophoresis procedure (BioRad Laboratories, Hercules, CA,
USA). The membrane was blocked at room temperature for 1 h in 5% milk powder in
Tris-buffered saline with Tween 20 (TBST) and then incubated at 4°C overnight with
primary antibodies; FABP4 (catalog number HPA002188; Sigma) and vinculin as a
loading control (catalog number V9131; Sigma). After washing with TBST, the
membranes were incubated with horseradish peroxidase-conjugated horse anti-rabbit
IgG (for FABP4) or anti-mouse IgG (for vinculin) (catalog numbers NA834 and NA931;
1:2000;

GE

Healthcare)

at

room

temperature

for

2

h.

An

enhanced
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chemiluminescence

detection

kit

(catalog

number

NEL104001EA;

Pierce

Biotechnology) was used to visualize the horseradish peroxidase signal.

Migration and invasion assay
Modified Boyden chambers (Coster, MA, USA) were coated with 0.1% gelatin
(migration) or defined basement membrane matrix (invasion). Defined basement
membrane matrix (for invasion) was prepared in a 10-ml stock solution with laminin
(50 µg/ml), 1 ml of type IV collagen (50 µg/ml), 0.2 ml of gelatin (2 mg/ml), and 4 ml
and 4.8 ml of PBS. In the upper chamber, HeyA8 MDR and Ovcar 5 cells (0.7 × 105)
suspended in 200 μl of serum-free media were added 48 h after siRNA/miRNA
transfections or Tamoxifen treatments. In the upper chamber, complete media for cells
containing 10% fetal bovine serum (500 μl) was added as a chemo-attractant. The
chambers were incubated at 37°C in 5% CO2 for 6 h (migration assay) or 24 h
(invasion assay). After incubation, the cells in the upper chamber were removed with
cotton swabs. Cells were fixed, stained, and counted using light microscopy. Cells
from five random fields were counted. Experiments were done in triplicate.

Tumor samples
High-grade ovarian tumor samples which are chemotherapy naïve were
obtained after the study was approved by the Institutional Review Board, and written
consent was obtained for the use of patient samples for research.

miR-409-3p expression in patient tumor samples as taken from GEO dataset
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The detailed method can be found in [83]. Briefly, 4 samples of HOSE (Normal
primary ovarian surface epithelial cells taken from normal postmenopausal women)
and 19 serous epithelial ovarian cancer samples were analyzed. The tumor samples
were of high-grade and contained more than 70% malignant epithelial cellularity. The
cloning frequency of a specific miR expressed as a fraction of total reads from a given
samples was used to compare the relative expression of miRNAs between samples.

In situ hybridization
In situ hybridization was done as previously described in [82] . High grade
serous ovarian cancer tissues which are chemotherapy naïve were selected. Xylene
and an ethanol dilution series were used for deparaffinization and rehydration of the
formalin-fixed, paraffin-embedded tissue sections. Tissue sections were digested with
15 µg/ml proteinase K for 20 minutes at room temperature and then loaded onto
Ventana Discovery Ultra (Tucson, AZ) for in situ hybridization analysis. The tissue
slides were then incubated with a double-digoxigenin-labeled miRCURY LNA miRNA
probe (Exiqon, Woburn, MA, USA) for 2 h at 55°C. Three percent H2O2 was used to
inactivate endogenous peroxidases. After incubation with polyclonal anti-digoxigenin
antibody and horseradish peroxidase-conjugated secondary antibody (Ventana), a
tyramine-conjugated fluorochrome (TSA) reaction was performed for 12 minutes.
Sequential TSA rounds were performed for the detection of proteins using the same
protocol. Slides were mounted with antifading ProLong Gold Solution (Life
Technologies).
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Immunostaining
Paraffin-embedded sections (5 µm) of tumor tissues were cut and used for
detection of FABP4. Formalin-fixed sections were deparaffinized by sequential
washings with xylene, 100% ethanol, 95% ethanol, 80% ethanol, and PBS. A suitable
antigen retrieval method was used. Endogenous peroxidase was blocked by
incubating the slides with 3% hydrogen peroxide in PBS. Nonspecific binding was
prevented by incubating the slides with 4% fish gelatin. This was followed by
incubation with primary antibody overnight at 4°C. The next day, the slides were
washed with PBS and incubated with suitable secondary antibody (goat anti-rabbit
horseradish peroxidase antibody diluted in protein block solution) for 1 h at room
temperature. The slides were then washed with PBS followed by development with
3,3'-diaminobenzidine. The nuclei were stained with Gill’s hematoxylin solution and
the slides were then mounted.

Quantitative real-time PCR
Total RNA was extracted from the tumor tissues using the Direct-Zol RNA
extraction kit (Zymo Research, Irvine, CA, USA). RNA was then quantified using a
NanoDrop spectrophotometer method and the 260 nm/280 nm ratios were checked
to determine quality. RNA (1 µg per sample) was reverse-transcribed into cDNA using
the Verso cDNA kit (Thermo Scientific, West Palm Beach, FL, USA) according to the
manufacturer’s protocol.
Quantitative real-time PCR was performed on a 7500 PCR system (Applied
Biosystems, Warrington, UK) using 1 µl of cDNA for each sample. SYBR green
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(Applied Biosystems) was used to detect the products, and 20 pmol of primer was
used for the reaction. All reactions were carried out with 20 µl of reaction mix and
performed in triplicate. We used the primers mentioned in Table 2. The following
conditions were used for PCR: 50°C for 2 minutes, then 95°C for 15 minutes, followed
by 40 cycles at 95°C for 1 minute each. All reactions were analyzed using the 7500
Applied Biosystems PCR software (v.2.0.5). The cycle threshold values of the target
genes were initially normalized to the cycle threshold values of 18S rRNA, and melt
curves were checked to determine the specificity of the reactions.
For miRNA quantifications, Taqman miRNA assays (Life Technologies) were
used and reverse-transcription real-time PCR was performed, according to the
manufacturer’s instructions. RNU6B was used as a housekeeping gene.

Copy number analysis
TCGA mRNA microarray (Agilent 244K Custom Gene Expression G4502A-07,
Affymetrix Human Genome U133A 2.0 Array, Affymetrix Human Exon 1.0 ST Array)
and RNASeqv2 level 3 and clinical data were retrieved from Broad GDAC Firehose
http://gdac.broadinstitute.org/. Putative copy-numbers from GISTIC were retrieved
from cbio portal (http://www.cbioportal.org/). To find the relationship between FABP4
expression and copy number, we first employed a Shapiro-Wilk test and verified that
the data doesn’t follow a normal distribution. The nonparametric test Kruskal-Wallis
test, was applied and no relationship between FABP4 and copy-number could be
established. A box-and-whisker plot (Box plot represents first (lower bound) and third
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(upper bound) quartiles, whiskers represent 1.5 times the interquartile range) was
used to visualize the data (log2(x)).

Correlation of FABP4 with genes from hypoxia metagene signature
The Spearman's rank-order correlation test was applied to measure the
strength of the association between FABP4 and the genes from the Winter et al.
hypoxia metagene[84]. We imposed a cut-off of functional relevance on the Spearman
correlation coefficient in absolute value of 0.2 based on the method published
previously [85].

Correlation of FABP4 expression with metabolites present in patient tumor
samples.
The metabolomics data and the gene expression data (normalized log values)
were taken from [58, 86, 87]. High grade serous ovarian cancer tumor samples (n=66)
were analyzed. The samples were divided into high or low FABP4 group based on the
median expression of FABP4 in all the samples. Similarly a median value for each
metabolite was calculated for high or low FABP4 samples. The comparison is
presented as antilog values.

DESI-MS imaging
DESI-MS imaging was conducted as described previously [88]. A 2D Omni
Spray (Prosolia Inc., Indianapolis, IN) coupled to an LTQ-Orbitrap Elite mass
spectrometer (Thermo Scientific, San Jose, CA) was used for tissue imaging. DESI-
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MS imaging was performed in the negative and positive ion mode from m/z 100 to
1500, using a hybrid LTQ-Orbitrap mass spectrometer which allows for tandem MS
experiments, high mass accuracy (<5 ppm mass error), and high mass resolution
(240,000 resolving power) measurements. The spatial resolution of the imaging
experiments was 200 µm. Spatially accurate ion images were assembled using
BioMap and MSiReader software. The histologically compatible solvent system
dimethylformamide:acetonitrile (DMF:ACN) 1:1 (v/v) was used for negative ion mode
analysis, at a flow rate of 1.2 µl/min. For positive ion mode analysis, pure ACN was
used, at a flow rate of 3 µl/min. The N2 pressure was set to 185 psi. For ion
identification, high mass resolution/accuracy measurements using the same tissue
sections analyzed were conducted. Tandem MS analyses were performed using both
the Orbitrap and the linear ion trap for mass analysis.

Histopathology and light microscopy
The same tissue sections analyzed by DESI-MS imaging were subjected
afterwards to standard H&E staining protocol. Light microscopy images of the H&E
stained slides were taking using the EVOS FL Auto Cell Imaging System (Invitrogen,
Thermo Fisher Scientific, Waltham, MA, USA).

Effect of Tamoxifen on expression of FABP4
The

drug

was

dissolved

in

DMSO

and

physiologically

achievable

concentrations were used for the experiments. HeyA8 MDR cells were plated in 24
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well plates and serum starved before tamoxifen treatment. The cells were collected
and RNA was extracted for qRT-PCR.

Free fatty acid uptake assay
The experiment was conducted as per the manufacturer’s instructions (Free
Fatty Acid Uptake Assay Kit (Fluorometric, ab176768) Cambridge, MA, USA). The
cells were serum starved and treated with tamoxifen at a desired concentration. Then
the fatty acid dye loading solution was added (100µl/ well of a 96 well plate). The
florescence signal was measured at Ex/Em 485/515 nm using a bottom read mode
after 30 minutes incubation at room temperature.

Survival analysis
Survival analysis was performed in R (version 3.2.5) using Tothill data set. The
relationship between overall survival, respectively progression free survival and
covariates (mRNA expression levels and clinical parameters (age and stage) was
examined using a Cox proportional hazard model. A multivariate Cox proportional
hazard model was fitted, including the clinical parameters and mRNA expression
significant in the univariate analysis.

Statistical Analysis
MS data corresponding to the areas of interest were extracted using
MSiReader software. The m/z range was discretized by performing hierarchical
clustering and cutting the resulting dendrogram at distance 0.05. Peaks appearing in
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more than 10% of the pixels were kept for analysis. Logistic regression was performed
with Lasso regularization using the “glmnet” package (26) in the R language.
Regularization parameters were determined by 3-fold cross-validation analysis. The
data were randomly equally divided into training and validation sets of samples, 5050 per patient basis. For other assays, Student’s t-test was performed to examine
the difference between the control and treatment groups. A P value less than 0.05
was deemed statistically significant. All the statistical tests were two-sided. Error
bars represent standard error from triplicates.
siRNA
Control siRNA
FABP4 siRNA seq 1
FABP4 siRNA seq 2

Primers
18S
FABP4
Mutated

Sequence
5'-UUAUGCCGAUCGCGUCACATT-3'
3'-TTAAUACGGCUAGCGCAGUGU-5'
5’-GACGUUGACCUGGACUGAAdTdT-3’
3’-UUCAGUCCAGGUCAACGUCdTdT-5’
5’-GUGGGAUAUAUUGUUCAAAdTdT-3’
3’-UUUGAACAAUAUAUCCCACdTdT-5’

Primer sequences
5’CGCCGCTAGAGGTGAAATTC3’ (forward) and
5’TTGGCAAATGCTTTCGCTC3’ (reverse)
5'-TGATGATCATGTTAGGTTTGGC-3' (forward) and 5'TGGAAACTTGTCTCCAGTGAA-3' (reverse)
CAACAATATCTTTTTGAACAATATATCCCACAGGCGACGGTAGAGTTCAAT
GCGAACTTCAGTCCAGGTCAA (forward)
TTGACCTGGACTGAAGTTCGCATTGAACTCTACCGTCGCCTGTGGGATAT
ATTGTTCAAAAAGATATTGTTG (reverse)

Table 2 siRNA and primer sequences used in the study
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Chapter 3: Molecular biomarkers for prediction of residual disease in ovarian
cancer
We used two publicly available datasets –TCGA and Tothill [77, 78] containing
samples of HGSOC (High grade serous ovaria cancer). We set up specific inclusion
and exclusion criteria for our analysis. We excluded samples if they were from
recurrent tumors, metastatic sites or normal tissues. We also excluded the tumors that
were not of high grade serous histology or were taken from patients who had
undergone neoadjuvant chemotherapy. From the two datasets, we thus selected 491
(TCGA) and 189 (Tothill) cases that met our criteria (Tumors that were taken from
primary site i.e. ovary, are chemotherapy naïve and are of stage 3 and above from
high grade serous histological subtypes).
From the TCGA dataset, 77% of the patients had RD while 74% of the patients
from the Tothill dataset had residual disease. We then analyzed the patient survival
data for these cases. We initially grouped them into 4 groups based on the size of the
residual disease

>20mm (n=102), 11-20mm (n=34), 1-10mm (n=242), No

macroscopic disease (n=113) for TCGA and macro-size NK/ exact size unknown
(n=13), >1cm (n=57), <1cm (n=66), nil (n=50) for Tothill dataset. Figure 7 (a and b)
shows the survival differences among these different groups. When we compared
overall survival of patients with R0 versus any RD (other 3 groups combined), we
noticed that R0 patients had significantly better overall survival compared to the rest
(Figure 7 c and d), p<0.0001 and p<001 for TCGA and Tothill respectively.
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Figure 7 Overall survival for the patients with high grade serous ovarian cancer,
grouped according to the size of the residual disease after primary debulking surgery.
TCGA (a) and Tothill (b) datasets were investigated. Analysis of TCGA (c) and Tothill
(d) patient datasets from the comparison of R0 to any residual disease (RD).
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We then used the clinical information of RD status and gene expression data
for the tumor samples collected from TCGA and Tothill datasets to identify genes
associated with increased incidence of residual disease. We only used the probe sets
that are common in TCGA and Tothill sets and recorded the mean expression of the
gene in RD group and R0 group. Table 3 shows the list of 47 probe sets (associated
with 38 genes) that have differences in their expression between RD and R0 group at
10% false discovery rate.
Gene

Probe set

ADAM12

213790_at

ADH1B

209612_s_at

ADH1B

209613_s_at

ADIPOQ

207175_at

ALDH1A3

203180_at

ALDH5A1

203609_s_at

AQP1

209047_at

BCHE

205433_at

COL11A1

37892_at

COL16A1

204345_at

COL3A1

201852_x_at

COL5A1

203325_s_at

COL6A2

213290_at

COL8A1

214587_at

CRISPLD2

221541_at
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CXCL12

203666_at

CXCL12

209687_at

CYR61

201289_at

DCN

201893_x_at

DCN

209335_at

DCN

211813_x_at

DCN

211896_s_at

ETV1

221911_at

FABP4

203980_at

FAP

209955_s_at

GADD45B

207574_s_at

GADD45B

209304_x_at

GADD45B

209305_s_at

GFPT2

205100_at

GREM1

218468_s_at

GREM1

218469_at

KCNE4

222379_at

LUM

201744_s_at

NBL1

201621_at

NBL1

37005_at

NFYA

204107_at

OMD

205907_s_at

PDGFD

219304_s_at
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PDLIM3

209621_s_at

PDPN

221898_at

POLR1C

207515_s_at

PTGIS

208131_s_at

SVEP1

213247_at

TIMP3

201150_s_at

VGLL3

220327_at

VSIG4

204787_at

XYLT1

213725_x_at

Table 3 List of 47 probe sets that have different expression in R0 and RD groups and
are common between TCGA and Tothill datasets (10% false discovery rate)

44

When the false discovery rate was lowered to 5%, we identified 8 genes that
differed in their expression between RD vs. R0 groups and were common in TCGA
and Tothill dataset. Figure 8 shows the heatmaps of the expression of those 8 genes
for TCGA (a) and Tothill (b) sets.

Figure 8 Heatmaps showing expression of top 8 genes that have different expression
between R0 and RD groups as observed in TCGA (a) and Tothill (b) datasets. (<5%
false discovery rate). The color bars at top indicate residual (red) or non-residual (blue)
cases. The red and blue bars within the map indicate high and low gene expression
respectively. High expression of FABP4 and ADH1B correlate with residual disease
incidences while low expression correlate with R0 incidences. The expression of
FABP4 and ADH1B correlate well with each other.
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We then investigated the density plots of the 8 genes presented in Figure 7.
We noticed that for FABP4 and ADH1B, the expression distribution was bimodal, as
opposed to the distribution of other genes which did not show a qualitative shift in their
expressions in RD and NoRD cases. For FABP4 and ADH1B, many samples had low
expression of these genes, however for a small set of samples, the expression was
very high. Nearly all the samples above a certain level of expression have RD. Figure
9 shows gene expression and RD status for FABP4, ADH1B in TCGA and Tothill sets.
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Figure 9 Dot and density plots for FABP4 (TCGA (a) and Tothill (b)) and ADH1B
(TCGA (c) and Tothill (d)) Cases with residual disease are represented in red while
non-residual disease is indicated in blue. Y axis represents normalized expression of
FABP4 or ADH1B and X axis represents number of samples from TCGA or Tothill
datasets. Increased rates of RD (red dots) is observed at high expression of FABP4
and ADH1B.
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We then decided to explore the joint distribution of gene expression of FABP4
and ADH1B (Figure 9). We measured the RD status when the expression of bothADH1B and FABP4 was high (using 3.5 as a cut of for both the genes). In TCGA
samples, 97 out of 107 (90.6%) samples belonging to the ‘high expression’ group had
RD whereas 281 out of 384 (73.2%) samples having low gene expression of ADH1B
and FABP4 had RD. Among the Tothill samples, 59 out of 63 samples (93.7%) of high
expression group had RD while 80 of 126 samples (63.5%) of low expression had RD.

Figure 10 Plots of FABP4 and ADH1B for TCGA (a) and Tothill (b) datasets. The rates
of residual disease (red dots) are higher when both the genes are elevated
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After identification of 2 possible biomarkers from the computational analysis,
we decided to perform validation studies in an independent cohort using qRT-PCR
method to determine gene expression. We examined 139 patient tumor samples from
two institutes- MD Anderson Cancer Center and Fred Hutchinson Cancer Research
Center. All the samples were chemotherapy naïve. We initially checked the expression
of ADH1B and FABP4 in omental samples as well and compared the gene expression
between ovarian and omental samples. Figure 11 shows the density plots for ADH1B
and FABP4 for both the tissues. For both the genes, the expression was higher in
omental tissues compared to ovarian tissues.

Figure 11 Density plots of FABP4 (a) and ADH1B (b) in ovary (red) and omental (gray)
as observed in qRT-PCR experiments
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We also checked FABP4 expression for 4 cases for which paired ovarian and
omental samples were available. In all these samples, omental gene expression was
higher than ovarian gene expression. (Percent difference- 2%, 85%, 110%, 131%).
We therefore decided to only focus on the samples from primary site a) To be
consistent with TCGA and Tothill data set b) The gene expressions were not
comparable between these two sites and cannot be analyzed using a same cut-off
values. The analyses of gene expression and RD were double-blinded. The qRT-PCR
values for ADH1B and FABP4 gene expression and RD statuses are presented in
Figure 11. As observed in the TCGA and Tothill datasets, the expression levels of
ADH1B and FABP4 were highly correlated with each other. However, the distribution
of these genes was different from the one observed in the microarray data of TCGA
and Tothill sets. The data from qRT-PCR analysis was not bimodal as observed in the
previous microarrays. Therefore, we decided to specify a threshold to determine which
samples will be grouped in high or low expression groups. Based on the power
calculations, we decided that 25% of the samples with the highest FABP4 expression
will be grouped together and we predicted that this group will have higher probability
of having RD compared to the rest of the samples. After unblinding the data and
correlating gene expression with RD statuses, we noticed that 30 out of 35 patients
predicted to have RD, had residual disease (PPV 86%). On the other hand, 54 out of
104 from the low FABP4 group had residual disease (PPV 52%). The odds ratio was
5.5 and the difference was significant (p=0.0002) using one sided Fischer’s exact test
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(Figure

12b).

Figure 12 (a) Plot of qRT-PCR values for FABP4 and ADH1B for the ovarian validation
samples. The solid line is the cutoff used for blinded validation while the dashed line
is the cutoff determined after weighting two genes equally (b) Prediction results for the
validation cohort after dividing the samples in high and low FABP4 groups
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When we further explored the relationship between ADH1B or FABP4 gene
expression and residual disease status (Figure 13 a and b), we noticed a continuous
trend of increasing incidence of RD observed with increase in gene expression. For
example, RD rate across the 4 groups of FABP4 genes was 41% (14/34, lowest
quartiles), 63% (22/35), 51% (18/35) and 86% (30/35, top most quartile)

Figure 13 Plots showing incidence of RD as a function of expression of FABP4 (a)
and ADH1B (b), based on qRT-PCR values from the validation cohorts. The points
show the incidence of RD for each group plotted at the mean value of FABP4 or
ADH1B per group. Horizontal and vertical lines indicate standard deviations
Our molecular biomarkers thus accurately predicted RD incidences in high
grade serous ovarian cancer.
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Chapter 4: Effects of FABP4 on tumor progression
After establishing the importance of FABP4 as a molecular biomarker, we next
explored if it has any functional role in tumor progression. We first silenced FABP4 in
HeyA8 MDR cells using FABP4 siRNA and made sure that we have achieved
significant FABP4 inhibition. We then conducted migration and invasion assays to
examine the effect of FABP4 knockdown on key steps in tumor metastasis.
After FABP4 siRNA transfection, there was 85-90% knockdown of FABP4. As
seen in Figure 14 (a and b) there was a significant reduction in the ability of cells to
migrate (p<0.01) or invade (p<0.01) after FABP4 knockdown. We also conducted
proliferation assay to make sure that the effect on migration and invasion is not a result
of stunted cell proliferation. There was no significant difference in cell proliferation after
FABP4. We then investigated the effect of ectopic expression of FABP4 in cancer
cells. In A2780 cells, ectopic FABP4 expression led to increase in migration (p<0.05)
and in invasion (p<0.01) (Figure 14 c and d).
The effect was also observed in additional cell lines such as Ovcar 5 and when
we used additional siRNA sequence. In Ovcar 5 cells, knockdown of FABP4 resulted
in significant reduction in migration (p<0.05) and inhibition (p<0.05) of the cells treated
with siFABP4 (Figure 14 e and f). The second sequence of siRNA was able to ~60%
decrease in migration (P<0.01) and ~65%decrease in invasion (p<0.01) (Figure 14 g
and h). Figure 14 i, j, k show the validation of FABP4 knockdown in the cells.
.
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Figure 14 (a, b) Effect of knockdown of FABP4 on the (a) migration and (b) invasion
of ovarian cancer cells (HeyA8 MDR). **p < 0.01. (c, d) Effect of increased expression
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of FABP4 on the (c) migration and (d) invasion of cancer cells (A2780-ip1). *p<0.05.
**p < 0.01. (e, f) Effect of FABP4 knockdown on (e) migration and (f) invasiveness
using a second siRNA sequence. **p<0.01. (g, h) Effect of FABP4 knockdown on (g)
migration and (h) invasion in Ovcar 5 cells. *p < 0.05. Validation of FABP4 knockdown
is shown for HMDR cell line FABP4 sirna (i) seq 1 (j) seq 2 (k) Ovcar 5 cell line
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Since the in vitro studies were promising, we decided to see if FABP4 promotes
tumor progression in in vivo settings. We first established a cell line (A2780)
ectopically expressing FABP4. We then injected control cells and cells ectopically
expressing FABP4 in the ovaries of nude mice and examined the effect of FABP4 on
promoting tumor burden and metastasis. Compared to subcutaneous or intraperitoneal injections, this orthotopic model closely mimics the cancer progression as
seen in ovarian cancer patients [89, 90]. There was no therapeutic intervention for this
study and the mice were sacrificed when any mouse became moribund. There was a
significant difference in tumor weight and number of nodules between control and
ectopic FABP4 group (Figure 15 a and b).We then analyzed H&E sections of the
tumors collected from these mice. We noticed that while tumors in the control group
did not invade the normal tissues, tumors from ectopic FABP4 group were highly
infiltrative (Figure 15 d). The metastatic pattern was also unique in the ectopic FABP4
group (Figure 15 e). In the control group, the tumor was mainly located in ovary,
peritoneum and mesentery whereas the metastasis in ectopic FABP4 was also
observed in diaphragm, liver, pelvis. As expected, immunohistochemical analysis
showed that FABP4 was indeed overexpressed in the tumors from ectopic FABP4
group (Figure 15 f).
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Figure 15 (a) Aggregate mass of tumors in orthotopic mouse models involving A2780ip1 cells transfected with control and FABP4 ectopic expression vectors (n = 10 mice
per group, Student t test). **p < 0.01. (b) Effect of ectopically expressed FABP4 on
the number of nodules in orthotopic mouse models involving A2780-control and
A2780-FABP4 ectopic expression (n = 10 mice per group, Student t test). **p < 0.01.
(c) Representative images of nodules are shown on the right. (d) Representative
hematoxylin and eosin-stained sections of tumor tissues from mice injected with
control A2780-ip1 cells or A2780-ip1 cells transfected with FABP4-expressing vector.
(e) Distribution of metastatic nodules present in the groups (f) Immunohistochemical
expression of FABP4 in tumor tissues from mice injected with control A2780-ip1 cells
or A2780-ip1 cells with ectopic expression of FABP4.
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The next step was to investigate the effects of FABP4 knockdown on tumor
progression. We used luciferase labeled HeyA8 MDR cell lines and performed intraovarian cell injections to establish orthotopic mouse model of ovarian cancer. A week
after the cell injections, we randomly divided the mice in two groups, one would receive
control siRNA encapsulated in DOPC nanoliposomes while the other group would
receive FABP4 siRNA encapsulated in DOPC nanoliposomes. The intra-peritoneal
DOPC injections were given twice weekly and the mice were sacrificed when any
mouse became moribund. At the end of the study, tumor weight, number of nodules,
locations of metastasis and weight of the mice were measured. As shown in Figure
16 a and b, FABP4 knockdown led to a significant reduction in tumor weight and
number of nodules. The metastasis was widespread in the control mice but was only
observed in the ovaries and peritoneal areas of mice injected with FABP4 siRNAs
(Figure 16 e). Bioluminescence images also supported the results. There was a
significant difference in luciferase readings between control mice and mice injected
with FABP4 siRNA (Figure 16 f). We also examined the tumor tissues for FABP4
expression. The treatment with FABP4 siRNA achieved significant knockdown of
FABP4 in mice as shown with immunohistochemistry and western blot (Figure 16 g
and h). We also recorded weight of the mice in these two groups and noticed that the
treatment

did

not

have

any

effect

on

the

mice

weight

(Figure

16d).
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Figure 16 (a) Aggregate mass of tumors in orthotopic mouse models involving HeyA8
MDR cells. Mice were treated with control or FABP4 siRNA encapsulated in DOPC
liposomes (n = 10 mice per group). **p < 0.01. (b) Effect of knockdown of FABP4 on
the number of metastatic nodules in HeyA8 MDR orthotopic mouse models. ***p <
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0.001. (c) Representative images are shown on the right. (d) Mouse weight in the
control and treatment groups. (e) Distribution of metastatic nodules present in
individual mice after treatment with control or FABP4 siRNA encapsulated in DOPC
liposomes. (f) Representative images of metastatic lesions revealed by luciferase
imaging, and quantitative assessment of luciferase signal from mice treated with
control or FABP4 siRNA encapsulated in DOPC nanoliposomes. *p<0.05. (g)
Immunohistochemical staining showing FABP4 protein expression levels at the
primary site (ovary) and metastatic sites after treatment with control or FABP4 siRNA.
(h) FABP4 protein expression levels at the primary site (ovary) and metastatic sites
after treatment with control or FABP4 siRNA, as shown in Western blot analysis. ODOptical Density.
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We also examined additional orthotopic mouse model. This time, we used
Ovcar 5 cell line, the siRNA treatment was similar to the one described above. At the
end of the study, we noticed significant inhibition of tumor progression in FABP4
siRNA treatment group. There was a significant reduction in tumor weight (Figure 17
a), number of nodules (Figure 17 b) and metastasis was also restricted to ovary and
mesentery unlike the extensive metastasis seen in control mice (Figure 17 c). The
treatment did not have any deleterious effect on body weight of mice (Figure 17 d).

Figure 17 (a) Aggregate tumor weight for mice injected with Ovcar 5 cell line. The
mice were treated with control siRNA or FABP4 siRNA encapsulated in DOPC
nanoliposomes. *p<0.05. (b) Effect of knockdown of FABP4 on the average number
of nodules. **p<0.01. (c) Pattern of metastasis in the control and treated mice. (d)
Mouse weight in the control and treatment groups.
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Aggressive cytoreduction as attempted in patients is not feasible in mice. To
determine if FABP4 knockdown affects the likelihood of achieving no residual status,
we calculated a score based on the metastasis pattern seen in the orthotopic mouse
models. We based our scoring schema on the one developed by Fagotti et al. [36].
The original schema assigns a score between 0-2 based on the extent of metastasis
at a given location. Studies have shown that the scores correlate with the residual
disease status in ovarian cancer patients [37, 38]. Figure 1 represents original
schema. Like Fagotti score, our modified scoring system (Figure 18 a) assigns a score
of 2 for each metastasis location and if the combined score for a specific mouse is
greater than or equal to 8, it was considered a case of residual disease. Conversely,
score below 8 indicated that R0 status. We calculated scores for each of the mouse
from the two in vivo experiments described above. Ectopic expression of FABP4 led
to higher scores in mice compared to the control mice (Figure 18 b). In the second in
vivo experiment, most of the mice treated with control siRNA had scores of 8 indicating
increased likelihood of residual disease; while all the mice treated with FABP4 siRNA
had scores below 8 (Figure 18 c). All the in vitro and in vivo experiments thus
established the key role FABP4 plays in residual disease occurrences in ovarian
cancer.
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Figure 18 (a) Scoring schema for the modified Fagotti score (b) Modified Fagotti
scores for each mouse in the control and ectopicFABP4 groups. (c) Modified Fagotti
scores for each mouse in the control siRNA and FABP4 siRNA groups. (Ov-Ovary,
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Perit-Peritoneum, M-Mesentery, S-Spleen, PS-Para-splenic area, H-Liver, PH-Parahepatic area, D-Diaphragm, LN-Lymph node, PALN-Para-aortic lymph nodule, omOmentum)
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Chapter 5: Upstream regulation of FABP4
We next investigated the upstream regulation of FABP4 in ovarian cancer. We
first analyzed TCGA data and checked if there is any correlation between copy
number and mRNA expression of FABP4. We investigated the data across various
platforms (Affymetrix Agilent, RNAseq2) however, there was no correlation between
copy number and FABP4 expression in TCGA ovarian cancer samples (Figure 19).

Figure 19 Correlation between copy number and mRNA expression levels of FABP4
across platforms (Affymetrix, Agilent, RNAseqv2) using data from The Cancer
Genome Atlas.
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We then compared FABP4 expression in ovarian cancer cell lines and
compared it with that of the tumor tissues taken from mice injected with the same cell
line. We noticed that FABP4 expression in tumor tissues is significantly higher
compared to its expression in the cell lines. We thus checked the effect of tumor microenvironmental factors on the expression of FABP4. We checked if 3D arrangement of
cells in the tumor tissue has any role in increasing FABP4 expression in vivo. The
effect was significant when compared to the cells grown in 2D condition, however it
was not consistent and did not validate in other cell lines. Effect of stromal cell lines
and hypoxia (Figure 24a) is discussed later in the next chapter. We also tested the
possibility of transcriptional regulation of FABP4. We analyzed TCGA dataset and
selected transcriptional factors (ISX, MSX, FOXA1) that had the highest correlation
with FABP4 expression across 3 platforms (Affymetrix, Agilent and Illumina).
Knockdown of some transcription factors resulted in downregulation of FABP4 thus
suggesting possible regulation by these factors but the chromatin immunoprecipitation
assay did not show binding between the selected transcription factor and the promoter
region of FABP4.
We thus decided to explore the possibility of miRNA regulation. We
systematically analyzed TCGA data to select the potential miRNAs regulating FABP4.
The selection process is explained in Figure 20a. We selected chemotherapy naïve,
high grade serous ovarian cancer samples from TCGA set. We then probed miRNA
data and selected miRNAs that have some association with FABP4 mRNA. We used
MIC (maximal information coefficient) scores to select miRNAs. In this system, a score
of 0 represents there is no association between a given miRNA and the expression of

66

gene while a score 1 indicates a perfect association between a miRNA and a gene.
The miRNAs with MIC > 0.2 were selected for further analysis. We used prediction
softwares to investigate which of these selected miRNAs are predicted to target 3’UTR
of FABP4. Table 4 lists the 32 miRNAs that had MIC scores of > 0.2 with FABP4 and
also lists the number of prediction softwares that predicted their interaction with
FABP4. After 2 selection criteria, we selected miR-409-3p which was predicted to
target FABP4 by the highest number of softwares (9 prediction softwares).
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Figure 20 (a) Flowchart showing the methods used to identify microRNAs (miRNAs)
that target FABP4 in ovarian cancer. (b) Effect of miR-409-3p mimic transfection
specifically on FABP4 expression levels (RNA) in HeyA8 MDR cells. (c) Effect of miR409-3p mimic transfection on FABP4 expression levels (protein) in HeyA8 MDR
cells.(d) Effect of miR-409-3p mimic transfection on the expression of FABP4 in Ovcar
5 cells. **p<0.01. (e) Effect of miR-409-3p mimic transfection on the expression of
FABP4 in Ovca 432 cells. *p<0.05. (f) Effect of miR-409-3p inhibitor on the expression
of FABP4 mRNA (left) and on the level of miR-409-3p (right) in Ovcar 3 cells. *p <
0.05.

MicroRNA

MIC score

Number

of

softwares

predicting miR-409-3p and
3’ UTR of FABP4
hsa-miR-143

0.270601

2

hsa-miR-126

0.22939

5

hsa-miR-214*

0.22323

1

hsa-let-7g*

0.22284

1

hsa-miR-199a-5p

0.22044

1

hsa-miR-409-3p

0.21971

9

hsa-miR-507

0.21927

1

hsa-miR-145*

0.21636

1

hsa-miR-214

0.21551

1

hsa-miR-1225-3p

0.21542

-
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hsa-miR-431

0.21531

2

hsa-miR-342-3p

0.21100

1

hsa-miR-199b-5p

0.21077

1

hsa-miR-145

0.21002

1

hsa-miR-150

0.20990

4

hsa-miR-133a

0.20808

1

hsa-miR-409-5p

0.20784

0

hsa-miR-199b-3p

0.20771

2

hsa-miR-22

0.20767

1

hsa-miR-22*

0.20705

1

hsa-miR-133b

0.20703

1

hsa-miR-1

0.20599

2

hsa-miR-1225-5p

0.20435

1

hsa-miR-514

0.20427

-

hsa-miR-132

0.20395

1

hsa-miR-152

0.20356

3

hsa-miR-432

0.20268

1

hsa-miR-508-3p

0.20240

2

hsa-miR-139-5p

0.20203

1

hsa-miR-379

0.20181

1

hsa-miR-182

0.20142

1

hsa-miR-143*

0.20019

1
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Table 4. miRNAs with MIC scores greater than 0.2 for association with FABP4 gene
expression
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We then checked the effect of miR-409-3p on FABP4 expression in vitro. We
transfected HeyA8 MDR cells with miR-409-3p mimic and observed 85% reduction in
FABP4 mRNA levels (p<0.01) (Figure 20 b). We saw a similar effect at protein level
(Figure 20 c). The effect was also observed in additional cell lines. In Ovcar 5 (Figure
20 d) and Ovca 432 cells (Figure 20 e), FABP4 levels were reduced after miR-409-3p
mimic transfection (p<0.01 and p<0.05 respectively).Conversely, when we transfected
Ovcar 3 cells with anti-miR-409-3p, we observed an increase in the expression of
FABP4 (Figure 20 f). There was 40% inhibition (Figure 20 g) after anti-miR-409-3p
transfection which resulted in a significant increase in FABP4 expression (p<0.05).
The next step was to investigate whether miR-409-3p binds to 3’UTR of
FABP4. The binding site for miR-409-3p on 3’UTR of FABP4 is shown in Figure 21 a
and the mutated sequence is shown in Figure 21 b. We conducted luciferase assays
to answer this question. We transfected HeyA8 MDR cells with plasmids containing
empty 3’UTR or 3’UTR of FABP4. The cells were then transfected with control miR or
miR-409-3p. When the luciferase activity was measured, we observed that the activity
was significantly lower for cells transfected with 3’UTR of FABP4 and miR-409-3p
compared to the controls (Figure 21 c) thus indicating that miR-409-3p binds to 3’UTR
of FABP4. We then mutated the sequence of 3’UTR of FABP4 where miR-409-3p is
predicted to bind. As observed earlier, there was a significant reduction in the
luciferase activity in the cells transfected with 3’UTR of FABP4 and miR-409-3p
however there was no significant difference between the controls and the cells
transfected with mutated 3’UTR of FABP4 suggesting that miR-409-3p can longer to
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bind to the mutated binding site of 3’UTR of FABP4 (Figure 21 d) . Thus luciferase
assay confirmed that miR-409-3p can bind to 3’UTR of FABP4.
We next assessed the expression of miR-409-3p in ovarian cancer cell lines
and compared it with its expression in normal ovarian cell line (HIO180). We noticed
that the expression of miR-4093p is significantly lower in the cancer cell lines
compared with the normal ovarian cell line (Figure 21 e). We also compared miR-4093p expression in ovarian tumor tissues and normal ovarian tissue using Gene
Expression Omnibus dataset (GSE15190) [83] (Figure 21 f). This data set also
revealed that tumor samples have low expression of miR-409-3p compared to the
normal tissues. We then examined 8 ovarian cancer patient tumor samples from the
Gynecology Oncology Dept. of M.D. Anderson Cancer Center. We used in situ
hybridization technique to analyze the expression of FABP4 and miR-409-3p. We saw
a distinct inverse association between miR-409-3p and FABP4 expression levels in
the in situ hybridization images (Figure 21 g).
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Figure 21 (a) Predicted binding site of miR-409-3p on the 3’ untranslated region (UTR)
of FABP4. (b) Original and mutated 3’ untranslated region (UTR) sequence of FABP4,
where miR-409-3p is predicted to bind. (c) Relative luciferase activity normalized to
that of cells transfected with an empty control and cells transfected with control
miRNA. HeyA8 MDR cells were transfected with empty control, wild-type FABP4and
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then transfected with a control miRNA mimic or a miR-409-3p mimic. **p < 0.01. (d)
Relative luciferase activity normalized to that of cells transfected with an empty control
and cells transfected with control miRNA. HeyA8 MDR cells were transfected with
empty control, wild-type FABP4 (red bar), or FABP4 with mutated 3’UTR (blue bar)
and then transfected with a control miRNA mimic or a miR-409-3p mimic. Activity was
measured 48 hours after transfection. *p < 0.05; **p < 0.01; NS indicates not
significant. (e) Expression of miR-409-3p in various ovarian cancer cell lines
compared with normal ovarian cells (HIO180). (f) Expression of miR-409-3p in normal
ovarian tissue and ovarian tumor samples in the GSE15190 dataset. (g) In situ
hybridization for miR-409-3p (green) and FABP4 (red) in tumor tissues from patients
with ovarian cancer (n = 8). Representative image is shown. Effect of miR-409-3p on
tumor progression.
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To investigate the effects of miR-409-3p on the metastatic abilities of cells, we
transfected HeyA8 MDR cells with control miR and miR-409-3p and 48 hours later
conducted migration and invasion assays. There was a significant reduction in the
number of cells migrated (p<0.01) and invaded (p<0.01) after miR-409-3p mimic
transfection (Figure 22 a and b). The effect was consistent in additional cell line and
Ovcar 5 cells decreased migration (p<0.05) and invasion (p<0.05) after miR-409-3p
transfection. On the other hand, when transfected with anti-miR-409-3p, there was an
increase in migration (p<0.05) and invasion of cancer cells (Figure 22 c and d).
To investigate whether the functions of miR-409-3p are mediated through
FABP4, we performed a rescue experiment (Figure 22 e). We initially established a
cell line (SKOV3 ip1) stably overexpressing a FABP4 construct lacking the 3’UTR.
Thus it would not be sensitive to a miR-409-3p mimic. We conducted luciferase
experiment as described above. SKOV3ip1 cells with FABP4 were significantly more
invasive (p < 0.05) compared to the controls. Transfection of the cell line ectopically
expressing FABP4 with miR-409-3p mimic did not lead to a significant decrease in
invasion compared to the control miR transfected cells. Thus, we concluded that
FABP4 could be the main target for miR-409-3p’s actions related to metastasis

75

Figure 22 (a,b) Effect of miR-409-3p mimic transfection on the (a) invasiveness and
(b) migration of HeyA8 MDR cells. **p < 0.01. (c,d) Effect of anti-miR-409-3p
transfection on (c) migration and (d) invasiveness of Ovcar 3 cells. *p < 0.05. (e)
Invasion potential of SKOV3 ip1 cells was assessed in control cells or cells ectopically
expressing FABP4 after transfection with control miRNA mimic or miR-409-3p mimic.
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Having established the tumor suppressive role of miR-409-3p in vitro, we
examined its effect in vivo. Similar to the previous experiments, we performed intraovarian cell injections of HeyA8 MDR to establish orthotopic mouse model. A week
after cell injections, mice were intraperitoneally injected with DOPC nanoliposomes
encapsulating control miR or miR-409-3p mimic twice weekly. At the end of the study,
mice were sacrificed and tumors were collected, weighed and location of metastases
were recorded. There was a significant reduction in the tumor burden as well as in the
number of nodules in the mice treated with miR-409-3p mimic (Figure 23 a and b). In
the control mice, the metastasis was observed at diaphragm, lymph nodes, pelvis,
perihepatic and perisplenic areas conversely in the mice treated with miR-409-3p
mimic the metastasis was mainly localized at ovary and mesentery (figure 23 c). We
also recorded the mice weight and noticed no harmful effects of the treatment on the
weight of the mice (figure 23 d).
We next checked the expression of FABP4 in tumor samples collected from
mice treated with miR-409-3p mimic. miR-409-3p mimic was able to significantly
reduce FABP4 expression in the in vivo setting. FABP4 mRNA expression decreased
after the miR-409-3p mimic injections (p<0.05) (Figure 23 e) but the effect was more
pronounced at the protein level as seen in western blot and immunohistochemical
staining (Figure 23 f and g respectively).
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Figure 23 (a) Aggregate mass of tumors in orthotopic mouse models of ovarian
cancer (HeyA8 MDR cell line) injected with control miRNA or miR-409-3p mimic
encapsulated in DOPC liposomes. **p < 0.01. (b) Effect of miR-409-3p mimic on the
number of nodules. Representative images are shown on the right. **p < 0.01. (c)
Distribution of tumor nodules in individual mice after treatment with control miRNA or
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miR-409-3p mimic. (d) The weight of the control and treated mice at the end of the
experiment. (e) Expression of FABP4 in tumor tissues after treatment with miR-4093p mimic treatment. *p < 0.05 (f) Effect of treatment with miR-409-3p mimic on the
expression of FABP4 (protein) in tumor samples (n = 3). **p < 0.01. (g) Representative
images of immunohistochemical analysis of FABP4 expression in mice treated with
control miRNA or miR-409-3p mimic.
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We next calculated the modified Fagotti scores for the mice in both the groups. Figure
24 shows the scores for individual mice from the control and miR-409-3p mimic
groups. Most of the mice from the control group had a score of 8 and above, thus
indicating increased likelihood of residual disease. On the other hand, mice treated
with miR-409-3p mimic had scores lower than 8, thus indicating that no residual
disease is likely to be achieved in these cases.

Figure 24 Modified Fagotti scores for individual mice from control miRNA and miR409-3p mimic groups.
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Chapter 6: Tumor micro-environmental factors regulating FABP4 and miR-4093p

We next decided to explore the tumor micro-environmental factors that can
affect the expression of miR-409-3p and FABP4. We examined the effect of stromal
components such as fibroblasts, mesothelial cells, endothelial cells and macrophages
on cancer cells and also studied the effect of hypoxic conditions on the expression of
FABP4 in ovarian cancer cells. We incubated cancer cells with the conditioned media
taken from endothelial fibroblasts, mesothelial cells or macrophages. For hypoxia
experiments, we subjected cancer cells to 1% hypoxia for 48 hours and collected the
cells for assessing FABP4 expression. Out of all the factors examined, hypoxia
consistently increased FABP4 expression in the cancer cells (Figure 25 a). In HeyA8
MDR cells, hypoxia treatment led to ~3 fold increase in FABP4 level (p<0.05) (Figure
25 b). The same effect was also observed in an additional cell line, Ovca 432. Hypoxia
treatment led to ~4 fold increase in FABP4 expression (p<0.05) (Figure 25 c). We then
decided to check the expression of miR-409-3p in these cells. Interestingly, miR-4093p expression was low in the hypoxia-treated cells compared to the control (p<0.05)
(Figure 25 d). The same effect was also observed in Ovca 432 cells, miR-409-3p
expression was inhibited by after hypoxia treatment (p<0.05) (Figure 25 e)
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Figure 25 (a) Effect of tumor micro-environmental factors on the expression of FABP4
(b c) Effect of hypoxia on (b) FABP4 expression and (c) expression of miR-409-3p in
HeyA8 MDR cells. (d, e) Effect of hypoxia on (d) miR-409-3p expression and (e)
FABP4 expression levels in Ovca 432 cells. *p < 0.05.
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We then decided to see if the similar effects can be seen in vivo. We used the
tumor samples that are collected from mice treated with bevacizumab. Bevacizumab
is anti-vascular endothelial growth factor and has been shown to increase hypoxia in
ovarian cancer patients [91]. We conducted immunohistochemical analysis of the
tumor sections with CA9 (Carbonic anhydrase 9, a hypoxia marker) and FABP4
antibodies. We observed consistent co-localization of CA9 and FABP4 in these
tissues (Figure 26 a). We further used the same samples for qRT-PCR analysis. We
checked the expression of miR-490-3p in the tumor samples treated with
bevacizumab and compared it with tumors treated with control antibody. The
expression of miR-409-3p was lower in the tumors treated with bevacizumab
compared to the control tumors (Figure 26 b).
After in vitro and in vivo experiments, we decided the check if the similar
regulation can be seen in the patient samples. We probed TCGA and Tothill datasets
for this analysis. We also used the hypoxia metagene signature as described in [84].
We extracted the gene expression data for FABP4 and for the genes mentioned in the
hypoxia metagene signatures.

We saw a positive correlation between FABP4

expression and the expression of many genes from the signature across various
platforms. Table 5 shows these correlations. Of particular mention was the gene
PLAU, plasminogen activator, urokinase. There was a significant correlation between
FABP4 and PLAU across all the platforms. Figure 26 c shows spearman correlations
between FABP4 and PLAU. We further checked if silencing of dicer affects the
expression of miR-409-3p. The qRT-PCR results indicated that knockdown of dicer
resulted in significant downregulation of miR-409-3p levels (Figure 26 d). Thus in vitro,
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in vivo and patient data, all point to the regulation of FABP4 and miR-409-3p by
hypoxia.

Figure 26 (a) Co-localization of CA9 (a hypoxia marker) and FABP4 in tumor tissues
taken from mice treated with bevacizumab, which is known to induce hypoxia.
Representative image is shown. (b) miR-409-3p expression levels in tumor tissues
from mice treated with control vehicle or bevacizumab, which is known to induce
hypoxia (n = 3 mice per group). (c) Direct correlation of FABP4 with PLAU (a hypoxia
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signature gene) in patient samples across different platforms. (d) Downregulation of
miR409-3p after knockdown of dicer (*p<0.05)

Table 5 Correlation of FABP4 gene expression with the expression of genes listed in
Winter hypoxia metagene signature across various data platforms
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Chapter 7: Downstream effects of FABP4 in cancer cells
We conducted reverse phase protein array (RPPA) to identify signaling
pathways regulated by FABP4. We compared two groups- HeyA8 MDR cells
transfected by control siRNA or by FABP4 siRNA. The heat map is shown in Figure
27 a. The confirmation of downregulation of FABP4 is presented in the western blot
(Figure 27 c). Several metastasis related proteins were suppressed in the cells where
FABP4 expression was silenced (Figure 27 b). We analyzed the RPPA data using
Ingenuity pathway analysis (IPA) and Netwalker softwares. The results from the IPA
analysis is presented in Figure 27 d. We noticed that several key pathways related to
cancer metastasis are downregulated in the cells where FABP4 is inhibited. The
results from Netwalker analysis also supported this results and revealed that several
subpathways related to metastasis are significantly downregulated in FABP4 siRNA
transfected

cells

(Figure

27

e).
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Figure 27 (a) RPPA data for downregulated proteins in the FABP4 siRNA and control
siRNA groups. (b) Proteins that were downregulated in the FABP4 siRNA group are
related to the metastasis pathway (c) Western blot for confirmation of downregulation
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of FABP4 in the samples submitted to RPPA (d) Ingenuity pathway analysis of RPPA
data. (e) Netwalker analysis of RPPA data.
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We next sought to identify the metabolomics changes regulated by FABP4. We
first analyzed the metabolite and gene array presented in [58, 86, 87]. We sorted the
patient tumor samples based on their expression of FABP4. Samples with FABP4
expression lower than the median were grouped in ‘Low FABP4’ group while those
with higher FABP4 expression than the median were grouped in ‘High FABP4’ group.
We then calculated median expression for each metabolite for samples present in
each group. Table 6 lists the metabolites that have different expressions depending
on the expression of FABP4. Low antilog value indicates low expression in low FABP4
group. We saw that several metabolites are different in high versus low FABP4
groups.
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BIOCHEMICAL NAME
glutathione, reduced (GSH)
N-acetylaspartate (NAA)
glycerophosphorylcholine (GPC)
glycerol 3-phosphate (G3P)
ascorbate (Vitamin C)
N-acetyl-aspartyl-glutamate-NAAGglucose 6-phosphate (G6P)
glutathione, oxidized (GSSG)
fructose-6-phosphate
1-palmitoylglycerophosphoethanolamine
adenosine-3-monophosphate-3 (AMP)
dehydroascorbate
obar-ribulose-5-phosphate-xylulose-5-phospha
1-arachidonoylglycerophosphoinositol2-oleoylglycerophosphoethanolamineglycerol 2-phosphate
1-palmitoylplasmenylethanolamine1-oleoylglycerophosphoethanolamine
dihydroxyacetone-phosphate-DHAPS-adenosylhomocysteine (SAH)
p-cresol-sulfate
phosphoenolpyruvate (PEP)
mannose-6-phosphate
1-palmitoylglycerophosphoinositol2-hydroxystearate
carnitine
gluconate
2-hydroxypalmitate
choline-phosphate
1-stearoylglycerophosphoethanolamine
butyrylcarnitine
docosahexaenoate (DHA; 22:6n3)
behenate-22-02-phosphoglycerate
7-alpha-hydroxy-3-oxo-4-cholestenoate-7-Hoca
4-hydroxybutyrate-GHB2-hydroxyglutarate
xylulose
erythronate*

Antilog
0.01906
0.15397
0.27502
0.30117
0.31861
0.49411
0.51071
0.54313
0.56294
0.5662
0.57108
0.57873
0.5815
0.58669
0.59617
0.60175
0.61374
0.61412
0.61641
0.62201
0.67683
0.67818
0.68185
0.68692
0.70347
0.70723
0.73625
0.73722
0.73992
0.74021
0.74046
0.74079
0.74804
0.75226
0.75483
0.7568
0.76382
0.77906
0.78137
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1-linoleoylglycerophosphoethanolaminepropionylcarnitine
ribitol
1-stearoylglycerophosphoinositol
inosine
6-phosphogluconate
dihomo-linolenate-20-3n3-or-n6adrenate (22:4n6)
arachidonate (20:4n6)
docosapentaenoate-n6-DPA-22-5n6ribose
1,3-dihydroxyacetone
phenylacetylglutamine
3-phosphoglycerate
spermidine
alpha-hydroxyisovalerate
bilirubin*E-Eadenosine-2-monophosphate-2 (AMP)
isobutyrylcarnitine
gamma-glutamylglutamate
1-oleoylglycerophosphoinositolisovalerylcarnitine
pyruvate
palmitoyl-sphingomyelin
ophthalmate
arabitol
4-androsten-3beta-17beta-diol-disulfate-1guanosine
malate
3-(4-hydroxyphenyl)lactate
succinylcarnitine
3-aminoisobutyrate
fumarate
flavin adenine dinucleotide (FAD+)
1-arachidonoylglycerophosphoethanolamine2-hydroxybutyrate (AHB)
pantothenate
eicosapentaenoate (EPA; 20:5n3)
beta-hydroxyisovalerate
caproate (6:0)

0.78458
0.78633
0.78647
0.78654
0.78697
0.78916
0.79142
0.79299
0.79409
0.79532
0.79596
0.79703
0.81738
0.81998
0.82124
0.8232
0.82466
0.82958
0.83273
0.83707
0.83845
0.8385
0.84004
0.84332
0.84399
0.8462
0.85172
0.85421
0.85855
0.86185
0.86332
0.86378
0.86417
0.86571
0.86664
0.87137
0.8716
0.87434
0.87622
0.87751
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glycylglycine
cholesterol
undecanedioate
glycerate
N1-methyladenosine
2-aminobutyrate
inositol-1-phosphate (I1P)
uridine
pyroglutamine*
pregnen-diol-disulfatenicotinamide
choline
glutamine
alanine
cytidine 5'-monophosphate-5-CMPcysteine-glutathione-disulfide
threonine
hypoxanthine
xanthosine
xanthine
acetylphosphate
pyrosphosphate (PPi)
leucine
isoleucine
cystathionine
myo-inositol
kynurenine
hippurate
urea
heptaethylene-glycol
methionine
gamma-glutamylleucine
acetylcarnitine
creatine
fructose
glutamate
N-formylmethionine
tryptophan-betaine5-oxoproline
glycine

0.8796
0.8799
0.88118
0.88232
0.88694
0.8875
0.88849
0.88874
0.88912
0.89145
0.89562
0.89575
0.89829
0.90003
0.90154
0.90385
0.90621
0.90661
0.90721
0.90767
0.9186
0.92256
0.92607
0.92645
0.92675
0.9276
0.93418
0.93739
0.9379
0.93795
0.93892
0.94026
0.94029
0.94166
0.94302
0.94468
0.94594
0.94846
0.95119
0.95285
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azelate (nonanedioate)
docosatrienoate-22-3n3N-acetylglycine
proline
phenylalanine
histidine
aspartate
pipecolate
N-acetylneuraminate
serine
1,5-anhydroglucitol (1,5-AG)
valine
glycolate (hydroxyacetate)
C-glycosyltryptophanmannose
mannitol
3-dehydrocarnitine*
2-aminoadipate
gamma-glutamylphenylalanine
stearate (18:0)
ribulose
5,6-dihydrouracil
pelargonate (9:0)
gamma-glutamylglutamine
tyrosine
putrescine
lactate
uracil
phosphoethanolamine
erythritol
urate
hexaethylene-glycol
N-acetylserine
ornithine
phosphate
sorbitol
ribose-5-phosphate
cystine
caprylate (8:0)
margarate (17:0)

0.95372
0.95406
0.95473
0.95505
0.95584
0.95635
0.95794
0.95885
0.95938
0.95978
0.96095
0.9626
0.96378
0.9671
0.9691
0.97312
0.97348
0.97574
0.97589
0.9774
0.97766
0.98053
0.98125
0.9821
0.98455
0.98462
0.98478
0.98781
0.98814
0.99101
0.99101
0.9922
0.99228
0.99386
0.99474
0.99577
0.99604
0.99679
0.99829
0.9988
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rboxy-4-methyl-5-propyl-2-furanpropanoate (CM
1
biliverdin
1
tetradecanedioate
1
ethanolamine
1.00054
asparagine
1.0009
myristate (14:0)
1.00993
hydroxyisovaleroyl-carnitine
1.01115
N-acetylthreonine
1.01121
palmitoyl-ethanolamide
1.01534
taurine
1.01649
gamma-aminobutyrate (GABA)
1.01724
arginine
1.01765
N6-acetyllysine
1.01896
laurate (12:0)
1.01939
creatinine
1.02247
N-acetylalanine
1.02297
hypotaurine
1.02305
assymetric-dimethylarginine (ADMA)
1.02316
nonadecanoate (19:0)
1.02736
methylphosphate
1.0274
tryptophan
1.0274
docosadienoate-22-2n61.03034
myristoleate (14:1n5)
1.03036
lysine
1.03382
argininosuccinate
1.03817
glycerol
1.03922
cysteine
1.03926
ergothioneine
1.04088
caprate (10:0)
1.04506
trans-4-hydroxyproline
1.0482
scyllo-inositol
1.04943
eicosenoate (20:1n9 or 11)
1.0505
riboflavin (Vitamin B2)
1.05709
gamma-glutamylvaline
1.05969
fructose-1-phosphate
1.06182
3-hydroxybutyrate (BHBA)
1.06391
palmitate (16:0)
1.06449
docosapentaenoate (n3-DPA; 22:5n3)
1.06805
maltose
1.0704
dihomo-linoleate-20-2n61.07442
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N-acetylmethionine
1.07588
N-acetylornithine
1.08646
15-HETE
1.09975
citrate
1.11086
pseudouridine
1.11583
stearidonate (18:4n3)
1.11806
5-methylpalmitate-isobar-with-2-methylpalmitat 1.11878
pentadecanoate (15:0)
1.12253
beta-alanine
1.12512
13-HODE-9-HODE
1.12574
cortisol
1.12874
3-methyl-2-oxovalerate
1.12939
succinate
1.13281
oleate (18:1n9)
1.13819
4-methyl-2-oxopentanoate
1.15256
2-linoleoylglycerophosphoethanolamine1.15983
N-acetylglucosamine-6-phosphate
1.1648
betaine
1.17065
glucose
1.17257
alpha-tocopherol
1.174
octadecanedioate
1.18455
linoleate (18:2n6)
1.19287
hosphate-glucose-1,6-diphosphate-myo-inosito 1.19868
phenol sulfate
1.2092
10-nonadecenoate (19:1n9)
1.22548
guanine
1.23592
hexadecanedioate
1.23857
linolenate [alpha or gamma] (18:3n3 or 6)
1.25673
palmitoleate (16:1n7)
1.26189
1-2-propanediol
1.26983
threonate
1.27318
maltotriose
1.30167
17-methylstearate
1.35496
stachydrine
1.38221
10-heptaadecenoate (17:1n7)
1.38914
1-stearoylglycerophosphocholine
1.4357
maltotetraose
1.63675
-docosahexaenoylglycerophosphoethanolamine1.67267
2-arachidonoylglycerophosphocholine*
1.75107
1-palmitoylglycerophosphocholine
2.54398
2-arachidonoylglycerophosphoethanolamine- 6.09392
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Table 6 Metabolites differentially expressed in patient samples belonging to low- and
high-FABP4-expression groups. Lower antilog value represents lower expression in
the low-FABP4 group.
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One of the limitations of this analysis was that the gene and metabolites arrays
were conducted on the entire tumor tissues.

Thus, the data could have been

influenced by the genes or metabolites present in the stromal cells. To address this
concern, we used Desorption Electrospray Ionization-Mass Spectrometry (DESI-MS
imaging) technique. The technique not only identifies metabolites present in a tissue
but gives the spatial information of the metabolite as well. For this experiment, we
used the chemotherapy naïve, high grade ovarian tumor samples used in our initial
biomarker discovery study. Based on their FABP4 expression, top 25% tumor samples
were classified in ‘high FABP4’ group while the rest of the samples were classified in
‘Low FABP4’ group. We then conducted DESI-MS imaging in both, negative and
positive polarities on 31 tumor samples.
The first step in the analysis was to check if there are sufficient differences in
the metabolites and lipids that can correlate with the changes in FABP4 expression.
Lasso (Least absolute shrinkage and selector operator) method was used to explore
the correlations between lipids, metabolites and FABP4 levels. The samples were
divided into training and validation groups. First, the training set was used to build a
molecular model. The coefficient of variation analysis on the negative ion mode data
from the training set, showed an overall agreement of 81.6%. The area under curve
(AUC) was 0.79. The result thus suggested an association between the expression
and composition of metabolites, and the expression of FABP4 in ovarian tumor
tissues. The model generated from the training set was used for the samples from the
validation set. When the negative ion mode data for the validation set was analyzed,
the overall agreement of was found to be 51.6% and AUC was 0.60 (Table 7 a). Similar
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methods were used for to analyze the positive ion mode data. The overall agreement
for the training set was 74.2% with AUC=0.73 while the validation set yielded the
overall agreement of 61.7% and AUC of 0.58 (Table 7 b). Thus, in both positive as
well as in negative ion mode, the results indicate an association between metabolites
and FABP4 expression.
We then decided to investigate if FABP4 levels can be predicted from the
metabolite information (Table 7). We combined positive and negative ion mode data
and built a comprehensive model. The data was then analyzed for each patient by
cross-validation method. The analysis successfully classified 66.7% of high FABP4
samples and 100% of low samples in the right categories. Molecular models based
on the lipid and metabolite data thus established that FABP4 expression can alter
metabolic

profiles

of

ovarian

cancer

tissues.

Table 7 (a) Model correlating molecular profiles and FABP4 expression based on
negative ion mode data
(b) Model correlating molecular profiles and FABP4 expression based on
positive ion mode data
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The next step was to identify the metabolites that are altered by FABP4
expression. We hence analyzed the data by SAM (Significant analysis of Microarray)
method and identified m/z values (mass to charge ratios) of the metabolites that differ
in their expression in low and high FABP4 groups. With the false discovery rate of
3.8%, we were able to identify 122 unique monoisotonic m/z values characteristic of
low FABP4 expression and 118 values characteristic of high FABP4 expression. We
then used high mass accuracy/high mass resolution and tandem mass spectrometry
analysis to identify the metabolite species associated with the m/z values. The species
identified belong to the following classes of metabolites- small metabolites, fatty acids
(FA),

sterol

lipids

monoacylglycerophosphates

(ST),

ceramides
(PA),

(Cer),

glycerolipids

glycerophosphoethanolamines

(GL),
(PE),

glycerophosphoglycerols (PG), glycerophosphoinositols (PI), glycerophosphoserines
(PS), and cardiolipins (CL).
There were several metabolites that were uniquely different in both the groups.
Table 8 and 9 lists all the metabolites present in low and high FABP4 groups. The
composition of fatty acids was significantly different in low vs. high FABP4 groups. An
increased number of highly unsaturated fatty acids was observed in high FABP4.
Oxidation of fatty acids was also specifically observed in high FABP4 group.
Glycerolipids,

glycerophosphoethanolamines,

glycerophosphoglycerols

and

lysophospholipid species, including LysoPE, LysoPG, and LysoPI were abundantly
present in high FABP4 group compared to low FABP4 group. Conversely, the number
of non-oxidized glycerophosphoinositols and glycerophosphoserines species was
higher in the low FABP4 samples compared to the high FABP4 group and cardiolipins
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were exclusively present in the low FABP4 samples. These observations suggest that
changes in the metabolic profiles of ovarian cancer tissues are associated with
variations in FABP4 expression.

Attribution
Metabolites
N-acetylaspartic acid
Ascorbic acid
Gluconic acid
Phosphatidic acid
Fatty Acids
FA 14:1
FA 17:0
FA hydroxy 16:0
FA 18:3
FA 18:2
FA 18:1
FA 18:0
FA 20:5
FA 20:4
FA 18:2
FA 18:1
FA hydroxy 20:4
FA 18:0
FA hydroxy 20:3
FA 22:6
FA 22:5
FA 22:4
FA 22:3
FA 20:4
FA hydroxy 22:6
FA 24:5
FA 24:4
FA 24:3
FA 22:4
FA hydroxy 24:0
Glycerolipids
MG 18:0
MG 22:6
DG 32:1/0:0
DG 32:0/0:0
DG 34:3/0:0
DG 34:2/0:0
DG 34:1/0:0
DG 36:4/0:0
DG 36:3/0:0
DG 36:2/0:0
DG 38:6/0:0
DG 38:5/0:0
DG 38:4/0:0

HUMAN SAMPLES - HIGH FABP4 EXPRESSION
Molecular
Mass error
Detected m/z
Formula
(ppm)

SAM
Score

C6H8NO5
C6H7O6
C6H11O7
C6H8O7Cl

174.0408
175.0252
195.0509
226.9962

0.0
2.3
0.5
0.9

-17.207
-5.943
-41.91
-6.776

C14H25O2
C17H33O2
C16H31O3
C18H29O2
C18H31O2
C18H32O2
C18H35O2
C20H29O2
C20H31O2
C18H32O2Cl
C18H34O2Cl
C20H31O3
C18H36O2Cl
C20H33O3
C22H31O2
C22H33O2
C22H35O2
C22H37O2
C20H32O2Cl
C22H31O3
C24H37O2
C24H39O2
C24H41O2
C22H36O2Cl
C24H47O3

225.1862
269.2484
271.2279
277.2171
279.2327
281.2484
283.2640
301.2171
303.2327
315.2092
317.2249
319.2284
319.2407
321.2427
327.2326
329.2482
331.2639
333.2794
339.2093
343.2296
357.2795
359.2953
361.3106
367.2416
383.3526

-0.9
0.7
0.4
0.7
1.1
0.7
1.1
0.7
1.0
1.3
1.3
-1.6
0.6
2.5
1.2
1.2
1.2
1.5
0.9
-5.0
1.1
0.8
1.7
-1.9
1.3

-23.744
-0.514
-13.784
-4.145
-11.127
-5.365
-3.589
-12.165
-27.378
-17.244
-21.336
-18.929
-22.176
-8.559
-21.309
-22.572
-37.569
-6.211
-32.242
-5.971
-16.621
-17.472
-0.934
-33.351
-2.796

C21H40O4Cl
C25H38O4Cl
C35H66O5Cl
C35H68O5Cl
C37H66O5Cl
C37H68O5Cl
C37H70O5Cl
C39H68O5Cl
C39H70O5Cl
C39H72O5Cl
C41H68O5Cl
C41H70O5Cl
C41H72O5Cl

391.2615
437.2459
601.4594
603.4758
625.4594
627.4754
629.4913
651.4753
653.4916
655.5072
675.4752
677.4932
679.5089

1.5
1.1
1.7
0.5
1.6
1.1
0.6
1.2
0.2
0.3
1.3
-2.2
-2.2

-7.537
-6.813
-8.245
-3.515
-2.261
-6.743
-14.24
-13.268
-4.762
-15.714
-18.92
-15.97
-15.44
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C43H70O5Cl
DG 40:7/0:0
C43H72O5Cl
DG 40:6/0:0
C43H74O5Cl
DG 40:5/0:0
Glycerophosphoethanolamines
C21H43NO6P
LysoPE P-16:0
C23H47NO6P
LysoPE O-18:1
C23H45NO7P
LysoPE 18:1
C23H47NO7P
LysoPE 18:0
C23H43NO7P
LysoPE 20:4
C26H43NO8P
PE 20:4/1:0
C23H47NO6P
PE 34:0
C41H73NO7Cl
PE P-18:0/18:4
C43H77NO7P
PE O-38:5 or PE P-38:4
C43H75NO8P
PE 38:5
C43H77NO8P
PE 38:4
C43H81NO8P
PE 38:2
C43H83NO8P
PE 38:1
C44H75NO8P
PE 39:6
C44H77NO8P
PE 39:5
C45H81NO7P
PE O-40:5 or PE P-40:4
C45H79NO8P
PE 40:5
C42H82NO8PCl
PE 37:1
C45H81NO8P
PE 40:4
C44H80NO8PCl
PE 39:4
C44H84NO8PCl
PE 39:2
C44H86NO8PCl
PE 39:1
C46H80NO8PCl
PE 41:6
C46H82NO8PCl
PE 41:5
C46H84NO8PCl
PE 41:4
C48H84NO8PCl
PE 43:6
C48H92NO8PCl
PE 43:2
Glycerophosphoglycerols
C22H44O9P
LysoPG 16:0
C24H44O9P
LysoPG 18:2
C24H46O9P
LysoPG 18:1
C28H44O9P
LysoPG 22:6
C40H72O10P
PG 34:3
C40H74O10P
PG 34:2
C40H76O10P
PG 16:0/18:1
C42H74O10P
PG 36:4
C42H76O10P
PG 18:2/18:1
C42H78O10P
PG 18:1/18:1
C44H74O10P
PG 38:6
C44H76O10P
PG 38:5
C46H74O10P
PG 40:8
C46H76O10P
PG 40:7
C46H78O10P
PG 40:6
C46H80O10P
PG 40:5
C50H74O10P
PG 22:6/22:6
Ceramides
C32H63NO3Cl
Cer d32:1
C33H65NO3Cl
Cer d16:1/17:0
C34H65NO3Cl
Cer d34:2
C34H67NO3Cl
Cer d34:1
C36H69NO3Cl
Cer d36:2
C36H71NO3Cl
Cer d36:1

701.4892
703.5063
705.5230

3.6
1.6
1.1

-2.8
-15.599
-15.089

436.2843
464.3159
478.2951
480.3109
500.2796
528.2728
718.5378
722.5116
750.5432
764.5224
766.5382
770.5657
772.5853
776.5221
778.5378
778.5764
792.5545
794.5485
794.5711
816.5310
820.5623
822.5761
840.5350
842.5495
844.5620
868.5641
876.6285

-2.3
-2.8
-2.5
-2.7
-2.6
-0.8
1.9
1.9
-1.2
-3.2
6.2
1.2
1.9
1.8
-1.0
0.5
-1.6
-0.8
0.7
0.7
2.9
-4.0
-2.7
1.1
-1.4
-3.4
0.8

-3.539
-30.415
-4.209
-5.842
-18.64
-36.177
-0.697
-10.493
-35.708
-24.395
-6.357
-4.115
-19.182
-17.599
-17.599
-20.071
-10.169
-4.871
-20.835
-4.447
-12.74
-16.628
-14.693
-26.422
-25.036
-7.314
-8.158

483.2734
507.2744
509.2881
555.2744
743.4890
745.5015
747.5196
769.5007
771.5201
773.5331
793.5010
795.5145
817.5011
819.5160
821.5309
823.5480
865.4996

-2.1
-3.1
-2.9
-0.7
-2.8
1.5
1.6
2.3
-2.5
0.9
1.9
4.7
1.7
2.7
3.5
1.8
3.4

-7.141
-20.225
-18.358
-11.491
-0.683
-1.249
-4.319
-18.539
-4.819
-2.341
-7.587
-2.768
-6.187
-2.822
-0.714
-0.707
-7.994

544.4519
558.4663
570.4655
572.4809
598.4960
600.5118

0.9
0.7
1.8
0.5
-1.7
-2.4

-8.899
-16.215
-8.47
-1.065
-4.673
-17.626
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Cer d38:1
Cer d41:2
Cer d42:0
Cer d42:1
PE-Cer d36:1
Monoacylglycerophosphates
PA 36:1
PA O-38:2 or PA P-38:1
Cardiolipins
CL 72:4
Glycerophosphoinositols
LysoPI 15:0
LysoPI O-16:0
LysoPI 18:0
Lyso PI 20:4
PI O-33:2 or PI P-33:1
PI P-18:0/17:2
PI O-35:2 or PI P-35:1
PI 37:4
PI 38:6
PI 38:5
PI 38:4
PI 40:4
PI 40:3
Glycerophosphoserines
PS O-36:4 or PS P-36:3
PS 38:4
PS O-39:0
PS O-40:4 or PS P-40:3
PS 39:2

C40H79NO3Cl
C41H79NO3Cl
C42H81NO3Cl
C42H83NO3Cl
C38H76N2O6P

656.5752
668.5766
682.5901
684.6068
687.5449

-0.1
-0.4
1.3
1.0
-0.4

-8.174
-1.288
-0.513
-1.236
-4.101

C39H74O8P
C41H79O7PCl

701.5120
749.5278

1.0
1.3

-18.155
-11.93

C81H148O17P2

727.5070

-1.9

-7.459

C24H46O12P
C25H50O11P
C27H52O12P
C29H48O12P
C42H79O12PCl
C44H81O12PCl
C44H83O12PCl
C46H80O13P
C47H78O13P
C47H80O13P
C47H82O13P
C49H86O13P
C49H88O13P

557.2729
557.3091
599.3199
619.2904
841.5011
867.5158
869.5312
871.5342
881.5159
883.5332
885.5483
913.5793
915.5952

0.5
0.9
0.5
-2.4
-1.0
0.2
0.5
3.3
3.1
1.1
1.8
2.1
1.7

-16.255
-5.78
-20.061
-15.733
-13.023
-15.209
-1.013
-3.616
-15.606
-15.194
-27.615
-18.087
-8.514

C42H75NO9P
C44H77O10NP
C45H89NO9P
C46H83NO9P
C45H83NO10P

768.5211
810.5279
818.6245
824.5810
828.5724

-3.4
1.5
4.3
0.1
4.3

-6.698
-0.461
-0.518
-12.284
-4.851

Table 8. High FABP4– human data – 122 m/z values

HUMAN SAMPLES - LOW FABP4 EXPRESSION
Attribution
Metabolites
Fumarate
Acetyl-glycine
Succinate
2-Hydroxy-3-methylbutyric
acid
Taurine
Pyroglutamate
Aspartate
3-Hydroxypicolinic acid
Glutamine
Glutamic acid
2-Hydroxyglutarate
Xanthine
Glycerophosphoglycerol

Molecular Formula

Detected
m/z

Mass error
(ppm)

SAM
Score

C47H84O13P
C4H6NO3
C4H5O4

115.0039
116.0351
117.0195

-1.7
1.7
-1.7

18.081
11.101
31.003

C5H9O3

117.0559

-1.7

19.079

C2H6NO3S
C5H6NO3
C4H6NO4
C6H4NO3
C5H9N2O3
C5H8NO4
C5H7O5
C5H3N4O2
C6H14O8P

124.008
128.0355
132.0305
138.0198
145.0621
146.0460
147.0302
151.0263
245.0430

-0.8
-1.6
-2.3
-0.7
-1.4
0.7
-2.0
-1.3
-0.8

27.304
8.295
18.919
40.807
20.826
26.925
21.018
37.65
18.354
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Glutathione
Fatty Acids
FA 8:0
FA 9:0
FA 15:0
FA 16:1
FA 20:3
FA 20:2
FA 20:1
FA 20:0
FA 22:0
FA 23:1
FA 23:0
FA 24:1
FA 24:0
FA 26:3
FA 26:2
FA 26:1
FA 26:0
Glycerolipids
DG 24:0/0:0
Glycerophosphoethanolamines
PE 18:1/1:0
PE 20:3/1:0
PE O-34:3 or PE P-34:2
PE O-34:2 or PE P-34:1
PE 34:2
PE 34:1
PE O-36:3 or P-36:2
PE 35:1
PE 36:3
PE 36:2
PE 38:3
Glycerophosphoglycerols
PG 18:0/18:1
PG 18:0/18:0
PG 38:4
PG 38:3
PG 38:2
PG 42:7
Ceramides
Cer d18:16:0
Cer m18:1/22:0
Cer m18:1/24:1
Cer m42:1
Cer d18:1/23:0
Cer d40:0(2OH)
Cer d42:1
Cer d42:0
Cer d18:1/25:0
Cer d18:1/26:1
Cer d18:1/26:0
PE - Cer 36:3
GlcCer d34:1
PE-Cer d37:1
Monoacylglycerophosphates

C10H82N3O6S

306.0762

2.6

42.764

C8H15O2
C9H17O2
C15H29O2
C16H29O2
C20H33O2
C20H35O2
C20H37O2
C20H39O2
C22H43O2
C23H43O2
C23H45O2
C24H45O2
C24H47O2
C26H45O2
C26H47O2
C26H49O5
C26H51O2

143.1079
157.1235
241.2183
253.2171
305.2483
307.2638
309.2795
311.2952
339.3264
351.3261
353.3420
365.3420
367.3578
389.3422
391.3578
393.3734
395.3889

0.7
-0.6
4.1
-0.8
-1.0
-1.6
2.3
-1.3
1.5
2.3
1.4
1.4
1.1
0.8
1.0
1.0
1.5

29.669
29.847
4.87
3.483
15.075
11.185
20.186
8.804
10.756
11.157
7.575
21.275
21.739
11.355
17.688
11.657
29.87

C27H51O5

455.3760

4.0

10.533

C24H45NO8P
C26H45NO8P
C39H73NO7P
C39H75NO7P
C39H73NO8P
C39H75NO8P
C41H77NO7P
C40H77NO8P
C41H75NO8P
C41H77NO8P
C43H79NO8P

506.2882
530.2912
698.5153
700.5272
714.5052
716.5221
726.5449
730.5368
740.5208
742.5378
768.5574

1.2
-4.5
3.3
2.1
3.8
2.1
0.8
3.3
3.8
1.9
-3.3

11.03
21.256
23.028
21.527
25.328
21.369
15.769
9.588
27.408
18.265
27.714

C42H80O10P
C42H82O10P
C44H78O10P
C44H80O10P
C44H82O10P
C48H80O10P

775.5482
777.5651
797.5313
799.5467
801.5634
847.5463

1.7
0.3
3.1
3.5
2.1
3.8

19.923
13.591
6.512
13.973
12.159
9.462

C34H69NO3Cl
C40H79NO2Cl
C42H81NO2Cl
C42H83NO2Cl
C41H81NO2Cl
C40H81NO4Cl
C42H83NO3Cl
C42H85NO3Cl
C43H85NO3Cl
C44H85NO3Cl
C44H87NO3Cl
C38H73N2O6PCl
C40H77NO8Cl
C39H79N2O6PCl

574.4962
640.5796
666.5975
668.6109
670.5895
674.5874
684.6068
686.6221
698.6223
710.6258
712.6369
719.4881
734.5323
737.5359

1.6
1.4
2.1
1.3
2.4
-2.1
0.1
0.3
0.3
4.9
1.5
2.6
2.7
1.5

13.104
7.264
20.026
16.913
5.698
16.897
10.001
21.885
11.719
11.435
6.835
11.341
5.86
14.674
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PA 32:0
PA 24:2
PA 24:1
PA 36:4
PA 36:3
Cardiolipins
CL 68:5
CL 70:7
CL 70:6
CL 70:5
CL 72:8
CL 72:7
CL 72:6
CL 74:10
CL 74:9
CL 74:8
CL 74:7
CL 76:10
CL 76:9
CL 76:8
CL 76:7
CL 36:4
Glycerophosphoinositols
LysoPI (16:0/0:0)
PI (32:1)
PI (32:0)
PI (34:2)
PI (34:1)
PI (O-23:0)
PI (25:1)
PI (36:4)
PI (36:3)
PI (36:2)
PI (36:1)
PI (37:3)
PI (38:6)
PI (38:3)
PI (40:6)
PI (39:4)
C13 PI (40:7)
Glycerophosphoserines
PS P-34:1
PS 16:0/18:1
PS P-36:2 or PS O-36:3
PS O-36:2 or PS P-36:1
PS 36:3
PS 36:2
PS 18:0/18:1
PS O-38:4 or P-38:3
PS 38:3
PS 38:2
PS 38:1
PS 40:6
PS 40:2
PS 40:1
PS 42:3

C35H68O8P
C37H68O8P
C37H70O8P
C39H68O8P
C39H70O8P

647.4678
671.4642
673.4814
695.4646
697.4801

3.2
2.2
1.6
1.6
1.9

17.343
17.925
22.269
11.851
12.823

C77H138O17P2
C79H138O17P2
C79H140O17P2
C79H142O17P2
C81H140O17P2
C81H142O17P2
C81H144O17P2
C83H140O17P2
C83H142O17P2
C83H144O17P2
C83H146O17P2
C85H144O17P2
C85H146O17P2
C85H148O17P2
C85H150O17P2
C45H82O15P2Cl

698.4716
710.4697
711.4767
712.4837
723.4791
724.4841
725.4941
735.4779
736.4852
737.4921
738.5015
749.4924
750.5045
751.5086
752.5161
959.4823

0.9
1.8
3.0
4.2
0.4
3.6
0.6
1.2
2.0
3.3
1.1
2.8
2.9
2.0
2.5
2.4

5.183
25.307
20.886
11.261
20.666
26.85
25.978
13.261
22.139
22.478
18.876
19.881
15.033
14.259
13.432
2.809

C25H48O12P
C41H76O13P
C41H78O13P
C43H78O13P
C43H80O13P
C42H83O12PCl
C44H82O13P
C45H78O13P
C45H80O13P
C45H82O13P
C45H84O13P
C46H82O13P
C47H78O13P
C47H84O13P
C49H82O13P
C48H85O13PCl
C49H81O13PCl

571.2899
807.5016
809.5141
833.5166
835.5321
845.5318
849.5519
857.5172
859.5347
861.5486
863.5655
873.5506
881.5196
887.5653
909.5472
935.5441
943.5110

1.8
1.6
5.6
2.4
2.5
0.2
-2.4
1.6
-0.6
1.5
2.8
-0.8
1.1
-0.2
-3.0
2.0
0.1

4.408
22.334
25.352
28.065
25.546
7.793
21.476
2.918
31.721
45.539
25.679
17.932
20.554
18.707
9.853
20.006
9.499

C40H75NO9P
C40H75NO10P
C42H77NO9P
C42H79NO9P
C42H75NO10P
C42H77NO10P
C42H79NO10P
C44H79NO9P
C44H79NO10P
C44H81NO10P
C44H83O10NP
C46H77O10NP
C46H85O10NP
C46H87O10NP
C48H87O10NP

744.5177
760.5149
770.5324
772.5490
784.5133
786.5279
788.5466
796.5467
812.5437
814.5577
816.5745
834.5271
842.5906
844.6056
868.6029

1.1
2.0
2.2
1.0
0.1
1.5
-2.4
3.9
1.2
3.3
1.8
2.4
1.3
2.0
-5.1

4.274
18.59
14.362
4.287
28.208
34.307
17.526
4.253
31.901
30.261
23.544
13.286
17.723
21.329
15.417
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PS 42:2
PS 42:1

C48H89O10NP
C48H91O10NP

870.6220
872.6369

-1.1
-1.9

17.786
20.275

Table 9. Low FABP4 – human data 118 m/z values
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For our next step of analysis, we decided to conduct DESI-MS imaging on in
vivo tumor tissues from one of our experiments. The two groups that we selected
were- Control siRNA and FABP4 siRNA. The metabolite profiles of these tissues
would be a direct result of the changes in FABP4 expression and hence is crucial to
understand how knocking down FABP4 can affect the metabolomics of cancer cells.
The primary results from these analyses are presented in Figure 28 and the detailed
analysis is presented in Table 10 and 11. There were 125 metabolites that were
unique to the control siRNA group while 59 metabolites were only present in the
FABP4 siRNA group. Similar to the patient analysis, we noticed more fatty acids and
glycerolipids in control siRNA (i.e. high FABP4 group) than FABP4 siRNA group (i.e.
Low FABP4 group). There was an enrichment of unsaturated and oxidated fatty acids
and lysophospholipids species in the control siRNA group. Interestingly we did not see
any fatty acid in FABP4 siRNA treated group. There were 50 metabolites that were
common between mice and human data when high FABP4 was considered while 26
species were found to be common in mice and human samples when low FABP4 data
was considered (Table 12 and 13).
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Figure 28 DESI-MS imaging pictures of in vivo tumor tissues. Representative pictures
show metabolites like glycerophosphoinositols (PI), glycerophosphoserines (PS),
glycerophosphoethanolamines (PE), glycerophosphoglycerols (PG) and fatty acids
(FA) are suppressed after FABP4 is knocked down with FABP4 siRNA. On the other
hand, ceramides are present in more abundance in FABP4 siRNA group compared to
the control group.
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Attribution

MICE SAMPLES - CONTROL - HIGH FABP4 EXPRESSION
Molecular
Detected
Mass error
Formula
(ppm)
m/z

Metabolites
Uracil
Taurine
Xanthine
Ascorbic acid
Citrate
Lauric Acid
Glycerophosphoethanolamine
Glucose
Norselic acid A
Fatty Acids
FA 8:0
FA 14:0
FA 15:0
FA 16:2
FA 16:1
FA 16:0
FA 18:3
FA 18:2
FA 18:1
FA 18:0
FA hydroxy 18:2
FA 19:1
FA 19:0
FA 20:5
FA 20:4
FA 20:3
FA 20:2
FA 20:1
FA 20:0
FA 18:2
FA 18:1
FA hydroxy 20:4
FA 22:6
FA 22:5
FA 22:4
FA 22:3
FA 22:2
FA 22:1
FA 20:4
FA 22:0
FA 24:6
FA 24:5
FA 24:4
FA 24:3
FA 24:2
FA 24:1
FA 22:4

SAM
Score

C4H3O2N2
C2H6NO3S
C5H3O2N4
C6H7O6
C6H7O7
C12H23O2
C5H13NO6P
C6H12O6Cl
C29H39O2

111.0199
124.0073
151.0260
175.0245
191.0193
199.1699
214.0481
215.0323
451.2859

0.9
0.8
-0.7
-1.7
-2.1
-2.5
-2.3
-2.3
-1.1

-7.573
-5.756
-6.716
-2.442
-9.995
-10.98
-12.602
-4.518
-11.045

C8H15O2
C14H27O2
C15H29O2
C16H27O2
C16H29O2
C16H31O2
C18H29O2
C18H31O2
C18H33O2
C18H35O2
C18H31O3
C19H35O2
C19H37O2
C20H29O2
C20H31O2
C20H33O2
C20H35O2
C20H37O2
C20H39O2
C18H32O2Cl
C18H34O2Cl
C20H31O3
C22H31O2
C22H33O2
C22H35O2
C22H37O2
C22H39O2
C22H41O2
C20H32O2Cl
C22H43O2
C24H35O2
C24H37O2
C24H39O2
C24H41O2
C24H43O2
C24H45O2
C22H36O2Cl

143.1076
227.2011
241.2166
251.2008
253.2167
255.2324
277.2167
279.2324
281.2480
283.2636
295.2271
295.2635
297.2792
301.2165
303.2322
305.2477
307.2634
309.2791
311.2946
315.2087
317.2245
319.2273
327.2321
329.2477
331.2639
333.279
335.2952
337.3102
339.2088
339.3258
355.2634
357.2789
359.2947
361.3103
363.3262
365.3416
367.2421

-1.4
-2.6
-2.9
-3.6
-2.4
-2.4
-2.2
-2.1
-2.1
-2.1
-2.7
-2.7
-2.4
2.7
2.6
2.9
2.9
2.6
3.2
2.9
2.5
1.9
2.8
2.7
1.2
2.7
1.2
3.0
2.4
3.2
2.5
2.8
2.5
2.5
1.9
2.5
-3.3

-10.212
-15.768
-13.172
-9.152
-16.69
-22.387
-14.723
-22.826
-22.745
-21.869
-8.968
-19.208
-16.768
-7.552
-22.184
-20.094
-21.457
-21.247
-15.449
-6.647
-6.058
-6.266
-16.919
-17.188
-20.922
-17.56
-18.522
-15.492
-6.08
-9.48
-16.981
-16.732
-21.34
-17.218
-17.659
-15.144
-7.137
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FA 24:0
FA 25:1
FA methyl 24:0
FA 26:5
FA 26:4
FA 26:3
FA 26:2
FA 26:1
FA 28:2
FA 26:0
Glycerolipids
MG 18:0/0:0
DG 36:3/0:0
DG 36:2/0:0
Glycerophosphoethanolamines
LysoPE 16:0
LysoPE 18:0
PE 34:2
PE P-18:0/18:4
PE O-36:3 or P-36:2
PE 36:3
PE 36:2
PE 36:1
PE O-38:5 or PE P-38:4
PE 38:5
PE 38:4
PE 40:6
PE 40:5
PE 40:4
Glycerophosphoglycerols
LysoPG 18:2
LysoPG 18:1
LysoPG 22:6
PG 16:0/18:1
PG 36:4
PG 18:2/18:1
PG 18:1/18:1
PG 38:2
PG 40:8
Monoacylglycerophosphates
PA 32:0
PA 24:2
PA 36:4
PA 36:3
PA 36:2
Cardiolipins
CL 72:8
CL 72:7
CL 72:4
CL 74:10
CL 74:9

C24H47O2
C25H47O2
C25H49O2
C26H41O2
C26H43O2
C26H45O2
C26H47O2
C26H49O2
C26H51O2
C26H51O2

367.3578
379.3573
381.3731
385.3105
387.3260
389.3416
391.3573
393.3734
395.3884
395.3885

1.1
2.4
1.8
1.8
2.3
2.3
2.3
1.0
2.8
2.5

-6.06
-5.221
-7.862
-16.964
-20.89
-16.232
-17.552
-12.345
-14.191
-6.23

C21H40O4Cl
C39H70O5Cl
C39H72O5Cl

391.2610
653.4908
655.5075

2.8
1.4
-0.2

-11.384
-3.08
-2.453

C21H43NO6P
C23H47NO7P
C39H73NO8P
C41H73NO7P
C41H77NO7P
C41H75NO8P
C41H77NO8P
C41H79NO8P
C43H77NO7P
C43H75NO8P
C43H77NO8P
C45H77NO8P
C45H79NO8P
C45H81NO8P

436.2821
480.3084
714.5062
722.5111
726.5417
740.5217
742.5372
744.552
750.5423
764.5217
766.5374
790.5403
792.5550
794.5707

2.8
2.5
2.4
2.6
-3.6
2.6
2.7
3.9
2.7
2.5
2.3
-1.4
-0.1
-0.3

-10.52
-13.315
-6.228
-18.191
-5.228
-9.691
-14.611
-10.896
-22.396
-11.709
-24.932
-15.82
-6.361
-18.501

C24H44O9P
C24H46O9P
C28H44O9P
C40H76O10P
C42H74O10P
C42H76O10P
C42H78O10P
C44H82O10P
C46H74O10P

507.2718
509.2876
555.2720
747.5160
769.5002
771.5152
773.5316
801.5639
817.5004

2.0
1.8
1.4
2.9
3.0
3.9
2.8
1.5
2.6

-8.529
-4.018
-7.775
-8.047
-12.51
-4.627
-5.956
-10.651
-6.68

C35H68O8P
C37H68O8P
C39H68O8P
C39H70O8P
C39H72O8P

647.4639
671.4641
695.4643
697.4804
699.4948

-2.8
2.4
2.0
1.4
3.1

-5.362
-5.662
-8.407
-9.11
-6.552

C81H140O17P2
C81H142O17P2
C81H148O17P2
C83H140O17P2
C83H142O17P2

723.4766
724.4834
727.5070
735.4758
736.4847

-3.0
4.6
4.3
4.1
2.7

-7.731
-8.549
-4.471
-6.673
-8.388
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CL 74:8
CL 74:7
CL 74:6
CL 79:10
CL 79:9
CL 79:8
CL 79:7
Glycerophosphoinositols
LysoPI 18:0
LysoPI 20:4
PI 36:4
PI 36:3
PI 36:2
PI 37:4
PI 38:5
PI 38:4
PI 38:3
PI 39:4
PI 40:6
PI 40:5
PI 40:4
Glycerophosphoserines
PS 36:4
PS 36:3
PS 36:2
PS 18:0/18:1
PS 38:4
PS 38:3
PS 38:2
PS 39:4
PS 39:3
PS 40:6
PS 40:4
PS 22:6/19:0
PS 41:4

C83H144O17P2
C83H146O17P2
C83H148O17P2
C85H144O17P2
C85H146O17P2
C85H148O17P2
C85H150O17P2

737.4922
738.5022
739.5074
749.4924
750.5026
751.5077
752.5180

3.1
0.1
3.7
2.8
-0.4
3.2
0.1

-16.348
-18.066
-16.188
-8.087
-5.903
-9.615
-5.77

C27H52O12P
C29H48O12P
C45H78O13P
C45H80O13P
C45H82O13P
C46H80O13P
C47H80O13P
C47H82O13P
C47H84O13P
C48H84O13P
C49H82O13P
C49H84O13P
C49H86O13P

599.3189
619.2868
857.5163
859.5312
861.5475
871.5332
883.5321
885.5474
887.5653
899.5629
909.5480
911.5627
913.5783

2.2
3.4
2.7
3.5
2.8
1.1
2.4
2.8
-0.2
2.9
-2.1
-3.1
3.2

-13.656
-7.542
-12.731
-8.368
-9.857
-7.472
-10.395
-17.953
-13.431
-8.627
-10.136
-11.638
-19.748

C42H73NO10P
C42H75NO10P
C42H77NO10P
C42H79NO10P
C44H77O10NP
C44H79NO10P
C44H81NO10P
C45H79NO10P
C45H81NO10P
C46H77O10NP
C46H81O10NP
C46H81O10NP
C47H83O10NP

782.4961
784.5119
786.5270
788.5429
810.5269
812.5416
814.5577
824.5432
826.5628
834.5269
838.5578
848.5439
852.5732

2.2
1.9
2.7
2.3
2.7
3.8
3.3
1.8
-2.9
2.6
3.1
0.9
3.3

-6.987
-4.53
-13.616
-10.371
-21.491
-12.988
-8.516
-9.394
-4.376
-12.156
-20.635
-10.301
-7.748

Table 10. Mice samples – Control - highFABP4 – 125 m/z values

Attribution
Metabolites
Succinate
Glutathione
Methymycin
Glycerolipids
DG 32:1/0:0
DG 34:2/0:0

MICE SAMPLES – siFABP4 - LOW FABP4 EXPRESSION
Molecular
Detected
Mass error
Formula
(ppm)
m/z

SAM
Score

C4H5O4
C10H16N3O6S
C25H43NO7Cl

117.0193
306.0756
504.2720

0.6
-2.9
-2.8

14.447
2.372
3.565

C35H66O5Cl
C37H68O5Cl

601.4593
627.4747

1.8
-2.2

5.518
4.196
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C37H70O5Cl
DG 34:1/0:0
C39H68O5Cl
DG 36:4/0:0
C39H74O5Cl
DG 36:1/0:0
C41H68O5Cl
DG 38:6/0:0
C41H70O5Cl
DG 38:5/0:0
C41H72O5Cl
DG 38:4/0:0
C43H68O5Cl
DG 40:8/0:0
C43H70O5Cl
DG 40:7/0:0
C43H72O5Cl
DG 40:7/0:0
Glycerophosphoethanolamines
PE 18:1
C24H45NO8P
C41H77NO8P
PE 36:2
C43H73NO8P
PE 38:6
C42H82NO8PCl
PE 37:1
C43H73NO8P
PE 38:6
C44H84NO8PCl
PE 39:2
Glycerophosphoglycerol
s
C38H72O10P
PG 22:1
C40H72O10P
PG 34:1
C42H78O9P
PG P-26:2 or PG O-36:3
C42H80O9P
PG P-36:1 or PG O-36:2
C42H80O10P
PG 18:0/18:1
C42H82O10P
PG 18:0/18:0
C44H72O10P
PG 38:7
C44H76O10P
PG 38:5
C48H76O10P
PG 42:9
Ceramides
C32H63NO3Cl
Cer d32:1
C34H65NO3Cl
Cer 34:2
C34H67NO3Cl
Cer 34:1
C34H69NO3Cl
Cer d18/16:0
C40H79NO2Cl
Cer m18:1/22:0
C40H77NO3Cl
Cer d40:2
C40H77NO3Cl
Cer d40:2
C42H83NO2Cl
Cer m42:1
C42H83NO3Cl
Cer d42:1
C42H85NO3Cl
Cer d42:0
C44H87NO2Cl
Cer m44:1
C44H85NO3Cl
Cer d18:1/26:1
C44H87NO3Cl
Cer d18:1/26:0
C50H95NO8Cl
GlcCer d34:2
C50H97NO8Cl
GlcCer d34:1
Cardiolipins
C79H138O17P2
CL 70:7
C79H140O17P2
CL 70:6
C83H140O17P2
CL 74:10
C83H142O17P2
CL 74:9

629.4914
651.4748
657.5229
675.4751
677.4903
679.5057
699.4742
701.4901
703.5063

-0.5
2.0
0.2
1.5
2.1
2.5
2.7
2.3
1.6

5.772
1.339
3.089
4.087
5.15
3.376
4.638
3.189
3.147

506.2876
742.5378
762.5040
794.5444
762.5040
820.5595

2.4
1.9
5.1
3.5
5.1
4.1

2.363
2.007
4.499
2.379
4.499
2.855

719.4857
743.4850
757.5385
759.5526
775.5482
777.5651
791.4848
795.5145
843.5146

1.7
2.6
0.5
2.5
1.7
0.3
2.7
4.7
4.3

2.984
2.738
8.120
3.118
4.647
5.331
2.043
2.059
5.532

544.4492
570.4644
572.4802
574.4960
640.5790
654.5585
656.5741
668.6107
684.6071
686.6207
696.6413
710.6239
712.6379
872.6757
874.6869

1.8
2.5
2.3
1.9
2.3
1.8
2.0
1.6
0.6
2.3
2.6
2.3
0.1
-0.6
4.5

2.891
5.907
5.537
3.892
3.255
5.066
2.583
6.489
9.328
6.922
5.418
3.455
7.647
4.767
6.519

710.4689
711.4755
735.4779
736.4852

3.0
4.6
1.2
2.0

4.073
2.794
0.599
1.58
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Glycerophosphoinositol
s
PI O-31:1 or PI P-31:0
Glycerophosphoserines
PS P-33:0
PS P-36:2 or PS O-36:3
PS O-36:2 or PS P-36:1
PS 18:0/18:1
PS O-39:0
PS 40:2
PS 40:1
PS O-41:0
PS 42:2
PS 42:1

C40H77O12PCl

815.4856

-1.1

2.002

C39H75NO9P
C42H77NO9P
C42H79NO9P
C42H79NO10P
C45H89NO9P
C46H85O10NP
C46H87O10NP
C47H93O9NP
C48H89O10NP
C48H91O10NP

732.5171
770.5324
772.5490
788.5466
818.6258
842.5894
844.6056
846.6582
870.6213
872.6357

1.9
2.2
1.0
-2.4
2.7
2.7
2.0
1.3
2.0
3.3

5.018
3.814
2.084
4.731
1.992
2.74
3.798
9.73
4.253
3.518

Table 11 Mice samples – siFABP4 - lowFABP4 – 59 m/z values

AGREEMENTS WITH HUMAN - CONTROL - HIGH FABP4 EXPRESSION
Molecular
Detected
Mass error
Attribution
Formula
(ppm)
m/z
Metabolites
C2H6NO3S
124.0073
0.8
Taurine
C5H3O2N4
151.026
-0.7
Xanthine
Fatty Acids
C18H29O2
277.2167
-2.2
FA 18:3
C18H31O2
279.2324
-2.1
FA 18:2
C18H33O2
281.248
-2.1
FA 18:1
C18H35O2
283.2636
-2.1
FA 18:0
C19H37O2
297.2792
-2.4
FA 19:0
C20H29O2
301.2165
2.7
FA 20:5
C20H31O2
303.2322
2.6
FA 20:4
C18H32O2Cl
315.2087
2.9
FA 18:2
C18H34O2Cl
317.2245
2.5
FA 18:1
C20H31O3
319.2273
1.9
FA hydroxy 20:4
C22H31O2
327.2321
2.8
FA 22:6
C22H33O2
329.2477
2.7
FA 22:5
C22H35O2
331.2639
1.2
FA 22:4
C22H37O2
333.2790
2.7
FA 22:3
C20H32O2Cl
339.2088
2.4
FA 20:4
2.8
C24H37O2
357.2789
FA 24:5
2.5
C24H39O2
359.2947
FA 24:4
-3.3
C22H36O2Cl
367.2421
FA 22:4
Glycerolipids
2.8
C21H40O4Cl
391.2610
MG 18:0/0:0
C39H70O5Cl
653.4908
1.4
DG 36:3/0:0
C39H72O5Cl
655.5075
-0.2
DG 36:2/0:0
Glycerophosphoethanolamines
2.8
C21H43NO6P
436.2821
LysoPE 16:0

SAM
Score

-5.756
-6.716
-14.723
-22.826
-22.745
-21.869
-16.768
-7.552
-22.184
-6.647
-6.058
-6.266
-16.919
-17.188
-20.922
-17.56
-6.08
-16.732
-21.34
-7.137
-11.384
-3.08
-2.453
-10.52
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LysoPE 18:0
PE P-18:0/18:4
PE O-38:5 or PE P-38:4
PE 38:5
PE 40:5
PE 40:4
Glycerophosphoglycerol
s
LysoPG 18:2
LysoPG 18:1
LysoPG 22:6
PG 16:0/18:1
PG 36:4
PG 18:2/18:1
PG 18:1/18:1
PG 40:8
Cardiolipins
CL 72:4
Glycerophosphoinositol
s
LysoPI 18:0
LysoPI 20:4
PI 37:4
PI 38:5
PI 38:4
PI 38:3
PI 40:6
PI 40:4
Glycerophosphoserines
PS 36:3
PS 38:4
PS 39:4

C23H47NO7P
C41H73NO7P
C43H77NO7P
C43H75NO8P
C45H79NO8P
C45H81NO8P

480.3084
722.5111
750.5423
764.5217
792.5550
794.5707

2.5
2.6
2.7
2.5
-0.1
-0.3

-13.315
-18.191
-22.396
-11.709
-6.361
-18.501

C24H44O9P
C24H46O9P
C28H44O9P
C40H76O10P
C42H74O10P
C42H76O10P
C42H78O10P
C46H74O10P

507.2718
509.2876
555.2720
747.5160
769.5002
771.5152
773.5316
817.5004

2.0
1.8
1.4
2.9
3.0
3.9
2.8
2.6

-8.529
-4.018
-7.775
-8.047
-12.51
-4.627
-5.956
-6.68

C81H148O17P2

727.5070

4.3

-4.471

C27H52O12P
C29H48O12P
C46H80O13P
C47H80O13P
C47H82O13P
C47H84O13P
C49H82O13P
C49H86O13P

599.3189
619.2868
871.5332
883.5321
885.5474
887.5653
909.5480
913.5783

2.2
3.4
1.1
2.4
2.8
-0.2
-2.1
3.2

-13.656
-7.542
-7.472
-10.395
-17.953
-13.431
-10.136
-19.748

C42H75NO10P
C44H77O10NP
C45H79NO10P

784.5119
810.5269
824.5432

1.9
2.7
1.8

-4.53
-21.491
-9.394

Table 12. Same species for human and mice samples - highFABP4 – 50 m/z values

AGREEMENTS WITH HUMAN - siFABP4 - LOW FABP4 EXPRESSION
Attribution
Molecular Formula Detected m/z Mass error (ppm) SAM Score
Metabolites
C4H5O4
117.0193
Succinate
14.447
0.6
C10H16N3O6S
306.0756
Glutathione
2.372
-2.9
Glycerophosphoethanolamines
506.2876
PE 18:1
2.363
C24H45NO8P
2.4
C41H77NO8P
742.5378
PE 36:2
2.007
1.9
C43H73NO8P
762.5040
PE 38:6
4.499
5.1
Glycerophosphoglycerols
C42H80O10P
PG 18:0/18:1
4.647
775.5482
1.7
C
H
O
P
777.5651
PG 18:0/18:0
42 82 10
5.331
0.3
C48H80O10P
847.5431
PG 42:7
6.468
7.6
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Ceramides
Cer d18/16:0
Cer m18:1/22:0
Cer m42:1
Cer d42:1
Cer d42:0
Cer d18:1/26:1
Cer d18:1/26:0
Cardiolipins
CL 70:7
CL 70:6
CL 74:10
CL 74:9
Glycerophosphoserines
PS P-36:2 or PS O-36:3
PS O-36:2 or PS P-36:1
PS 18:0/18:1
PS 40:2
PS 40:1
PS 42:2
PS 42:1

C34H69NO3Cl
C40H79NO2Cl
C42H83NO2Cl
C42H83NO3Cl
C42H85NO3Cl
C44H85NO3Cl
C44H87NO3Cl

574.4960
640.5790
668.6107
684.6071
686.6207
710.6239
712.6379

1.9
2.3
1.6
0.6
2.3
2.3
0.1

3.892
3.255
6.489
9.328
6.922
3.455
7.647

C79H138O17P2
C79H140O17P2
C83H140O17P2
C83H142O17P2

710.4689
711.4755
735.4779
736.4852

3.0
4.6
1.2
2.0

4.073
2.794
0.599
1.58

C42H77NO9P
C42H79NO9P
C42H79NO10P
C46H85O10NP
C46H87O10NP
C48H89O10NP
C48H91O10NP

770.5324
772.5490
788.5466
842.5894
844.6056
870.6213
872.6357

2.2
1.0
-2.4
2.7
2.0
2.0
3.3

3.814
2.084
4.731
2.74
3.798
4.253
3.518

Table 13. Same species for human and mice samples - lowFABP4 – 26 m/z values
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Effect of FABP4 expression on overall and progression-free survival
We queried Tothill ovarian cancer patient data set to investigate the association
between FABP4 and overall and progression-free survival. The data were available
for 2 probesets for FABP4. Using multi-variate analysis, we observed that there was
a significant correlation between high FABP4 expression and overall survival (Figure
29 a) and with progression-free survival (Figure 29 b) for both the probe-sets. For the
univariate analysis as well, high FABP4 correlated with poor overall (Figure 29 c) and
progression-free

survival

(Figure

29

d).
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Figure 29 (a) Multivariate analysis of FABP4 (for two probes) for overall survival using
Tothill data set. (b) Multivariate analysis of FABP4 (for two probes) for progressionfree survival using Tothill data set (c) Univariate analysis for FABP4 using Tothill data
set for overall survival (d) Univariate analysis for FABP4 using Tothill data set for
progression-free survivalFABP4 in uterine cancer
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Chapter 8: FABP4 as a predictor of residual disease in uterine cancer
Having established the importance of FABP4 in residual disease of ovarian
cancer, we decided to investigate if it can be used as a predictor for other cancer types
as well. We selected uterine cancer since the standard of care for this cancer is similar
to that of ovarian cancer (Primary debulking surgery followed by adjuvant
chemotherapy). We initially checked FABP4 expression in uterine cancer cell lines
and noticed that the expression is considerably low (Figure 30 a). However,
sometimes tumor micro-environment can induce certain gene expressions. We hence
decided to check expression of FABP4 in tumor samples collected from uterine cancer
mouse models. We checked the expression on tumor collected from SKUT2, HEC1a,
ISHIKAWA and SPEC2 mouse models and compared it to the HeyA8 MDR mouse
model (Positive control) staining. We noticed that uterine tumor tissues do express
FABP4 in vivo (Figure 30 b). The next step was to investigate patient data base and
explore the association between FABP4 expression and incidences of residual
disease. We analyzed TCGA data and segregated the samples as endometrioid or
serous. The samples were then divided into residual disease (RD) or no residual
disease (R0) groups. There was however, no significant correlation between FABP4
expression and residual disease incidences in both of these groups (Figure 30 c and
d). We thus concluded that relation between FABP4 and RD is unique for ovarian
cancer.
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Figure 30 (a) Expression of FABP4 in a uterine cancer cell line panel. (b)
Immunohistochemical staining showing expression of FABP4 in in vivo mouse models
of uterine cancer. (c, d) Relation between FABP4 and residual disease status in (c)
endometrioid and (d) serous subtypes of uterine cancer, R0- No residual disease, RDResidual disease (TCGA patient database).
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Chapter 9: Therapeutic options to target FABP4 in patients
Our results thus far recognize FABP4 as a promising therapeutic target for
ovarian cancer patients. Our next step, therefore, was to search for clinically approved
drugs that can target FABP4. In a recent study, tamoxifen, a selective estrogen
modulator, has been shown to inhibit FABP4 in macrophages [92]. We decided to
check if it can suppress FABP4 in ovarian cancer cells. We used physiologically
relevant concentrations of tamoxifen and checked its effects on FABP4 expression.
We treated HeyA8 MDR cells with various concentrations of tamoxifen, for different
time intervals. At a concentration of 3.5 uM, after 24 hours, tamoxifen inhibited FABP4
expression by more than 50% (p<0.0.5) (Figure 31 a). We then decided to check if
this inhibition was functionally relevant. We first conducted free fatty acid uptake
assay. Since FABP4 plays a key role in uptake and metabolism of fatty acids, this
assay reflects if inhibition of FABP4 was sufficient enough to affect its functions.
Tamoxifen inhibition of FABP4 significantly impaired the ability of cancer cells to
uptake free fatty acids as shown in Figure 30 b (p<0.01). We also checked if we see
any effect on metastasis related pathways. We noticed that inhibition of FABP4 by
Tamoxifen suppressed migratory ability by cancer cells significantly p< 0.05 (Figure
30 c). Tamoxifen is thus a potential candidate for FABP4 inhibition in ovarian cancer.
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Figure 31 (a) Effect of tamoxifen treatment on the expression of FABP4 in HeyA8
MDR cells. *p<0.05. (b) Effect of tamoxifen treatment on the ability of cancer cells to
take up free fatty acids (HeyA8 MDR cells). **p<0.01. (c) Change in the migratory
potential of cancer cells after tamoxifen treatment (HeyA8 MDR cells). *p<0.05.
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Chapter 10: Discussion
Systematically

combining

clinical

data,

experimental

models

and

bioinformatics, we explored the underlying biology of residual disease in ovarian
cancer. Using publicly available datasets we have shown that high expression of
FABP4 and ADH1B can predict increased likelihood of residual disease in ovarian
cancer patients. The results were also validated by additional patient cohorts taken
from two cancer institutes. If confirmed by additional external validations, this study
has potential applications in the clinical settings for personalized treatment
approaches. If a patient has high likelihood of having residual disease after the
debulking surgery, it would be more beneficial to give her neoadjuvant chemotherapy
first. It might increase chances of achieving complete cytoreduction at interval
debulking thus improving patient prognosis. Avoiding unnecessary surgeries will also
reduce the surgery-associated morbidities in patients. Thus, it is crucial to personalize
the treatment options (NACT or PDS) based the residual disease predictions for a
given patient.
Previous studies have employed CT scans or CA-125 levels for prediction of
suboptimal cytoreduction, but they do have certain limitations [20, 29, 30]. Most of the
studies used old classifications of ‘optimal’ and ‘suboptimal’ cytoreduction. Recent
studies have established the importance of R0 resection making the old classification
system inadequate to assess prognostic impact. Thus, some of the earlier studies may
not be valid any longer since the markers were not particularly used to study R0/RD
status. Many CT scan based studies also lack external validity [13, 34] .
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Recent studies have explored the gene signatures of residual tumors of ovarian
cancer. A study of 213 ovarian cancer patients showed that tumor samples
simultaneously overexpressing GLUT-1 and Ki-67 were more likely to get suboptimally
cytoreduced than other tumor samples [93]. Another study with 44 advanced serous
ovarian cancers identified 120 genes that were differentially expressed between
optimally and suboptimally cytoreduced tumors. A predictive model consisting of 32
genes was able to predict optimal or suboptimal debulking with 72.7% accuracy [94].
Several of the genes found to be predictors of suboptimal disease were linked with
increased metastasis in ovarian cancer. The study however did not validate in internal
cross-validation. Other genes including IGF1R, VEGF-C, SRA1, TGFβ1, CAR3/7,
CAR4/7, RNAse III Dicer have been found to be associated with suboptimal debulking
of ovarian cancer [95-100]. Certain proteins such as cyclin E, c-erb-B-2, Twist, p63α,
ERCC1, AEG-1, P130cas have also been found to be correlated with increased
likelihood of suboptimal cytoreduction [101-107]. Immunoprofiling of 232 ovarian
tumors have shown increased number of T-regulatory cells (CD4+CD25+ T cells) in
suboptimally resected patient samples compared to the samples from optimally
debulked patients [108]. Epigenetic modifications have also been linked with surgical
outcome. HOXA11 methylation levels have been found to be significantly different
between <2cm residual disease and > 2cm residual disease [109]. A large study
based on meta-analysis of 1525 samples of primary, late stage high-grade serous
ovarian tumors has revealed a gene signature that is differentially expressed in
optimally suboptimally cytoreduced tumors. Validations studies using qRT-PCR and
immunohistochemical staining have revealed POSTN, CXCL14, phosphorylated
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Smad2/3 as independent predictors of debulking status. The model based on these
three proteins was able to classify high and low risk samples with 92.8% accuracy.
Pathways analysis of this gene signature revealed activation of TGF-β1/Smad
signaling pathway, RTK/Ras/MAPK/Erg-1, AMPK/Erg-1 and Hedgehog/Gli signaling
in tumors taken from suboptimally cytoreduced patients [110]. Although these studies
have several limitations; such as small number of samples, lack of independent
validation, inclusion of heterogeneous tumor types, grades and varying definitions of
optimal, suboptimal instead of R0, RD cases etc.; they indicate that tumor biology
plays a crucial role in determining the surgical outcome of ovarian cancer patients.
In the light of the limitations of other studies, our study to identify molecular
predictors is unique for the following reasons: 1) We used R0 and RD as our clinical
endpoints. Various studies have shown that there is a larger difference in overall
survival between R0 and RD patients compared to the difference between optimal and
suboprimal surgeries. Moreover, the definition of R0 is consistent across all the
centers contrary to the definitions of optimal cytoreduction which vary. 2) The assay if
approved will be used for patients who had not received any prior chemotherapy.
Hence, we only focused on primary tumors of high grade serous ovarian cancer from
patients who had not received any neoadjuvant chemotherapy or surgery. 3) To avoid
batch effects, we used two different datasets, confirmed the results in a separate
patient dataset and validated it experimentally using another separate patient cohort.
4) To make the test clinically feasible, we restricted the selection to a small number of
predictors. 5) The odds ratio for prediction by CA-125 levels are lower than our
prediction of residual disease using FABP4 expression [24, 111].
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However, compared to the clinical data such as CT-scans, CA-125 levels or
laparoscopic measurements; information about molecular predictors would be less
readily available to the surgeons. Hence, predictions using molecular biomarkers
would probably be combined with laparoscopic assessment to predict RD status of a
patient.
Little is known about the biology of residual disease in ovarian cancer. This
study not only delineates the downstream signaling of FABP4 leading to residual
disease, it also investigates the regulation of FABP4. Hypoxia has been known to
promote tumor progression however, its exact role in the pattern of metastasis was
not known. We show that hypoxia suppresses miR-409-3p thus removing FABP4
inhibition which leads to FABP4 upregulation ultimately leading to residual disease.
miR-409-3p has also been studied in various types of cancers such as gastric,
colorectal, breast, prostate, glioblastoma, fibrosarcoma and osteosarcoma. In
glioblastoma, miR-409-3p has been shown to regulate O6-methylguanine-DNA
methyltransferase (MGMT) [112]. It also suppresses glioma cell proliferation and
invasion by targeting HMGN5 [113]. In colon cancer, miR-409-3p can suppress Beclin1 and thus inhibits chemotherapy induced autophagy and sensitizes the cancer cells
to chemotherapy. Its expression is also lower in colorectal cancer tissues compared
to the adjacent non-tumor tissues. In addition to Beclin, NLK and GAB1 have been
shown to be targets of miR-409-3p [114-116]. In fibrosarcoma cell line HT1080; miR409-3p suppresses tumor growth, vascularization and metastasis by targeting
angiogenesis (ANG) [117]. miR-409-3p has been extensively studied in breast cancer.
It has been shown to suppress proliferation, migration and invasion of breast cancer
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cell lines and shown to inhibit tumor progression possibly by downregulating its target
genes such as AKT and ZEB1 [118, 119]. Patient sample analyses have also shown
that its expression is low in tumor tissues compared to normal breast tissue
specimens. Moreover, it has also been suggested as a detection and prognostic
marker of breast cancer since its plasma levels are found to be lower in cancer
patients compared to the normal controls [120, 121]. The importance of miR-409-3p
as a tumor suppressor has also been studied in gastric cancer. It is significantly
downregulated in gastric cancer cell lines and tumor tissues compared to nontumorous samples. Moreover, its expression is lower in patients with lymph node
metastasis compared to the patients without lymph node metastasis [122]. In gastric
cancer, radixin and PHF10 are shown to be the targets of mir-409-3p [122, 123]
whereas in osteosarcoma it inhibits metastasis and tumor progression by targeting
CTNND1 [124]. In addition, it also acts as a tumor suppressor in lung adenosarcoma
and bladder cancer by targeting c-Met [125]. While it acts as a tumor suppressor
miRNA in glioblastoma, osteosarcoma, fibrosarcoma, lung, breast, gastric and colon
cancers, it is known to promote tumor progression in prostate cancer. Higher
expression of miR-409-3p has been observed in prostate cancer cell lines and tissues
than the normal controls. It increases expression of EMT and stemness markers in
cancer cells and. Delivery of miR-409-3p/5p induced tumors in mice in vivo.
Conversely inhibition of miR-409-5p led to reduced metastasis and improved survival
[126, 127]. The role of miR-409-3p in ovarian cancer has not been studied yet and our
study describes its role in regulation of FABP4 and residual disease of ovarian cancer.
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FABP4 has been shown to be present in adipocytes, macrophages,
endothelial cells as well as in dendritic cells. In these cell types as well, it is known to
promote tumor progression by increasing angiogenesis, inflammation or by providing
energy from adipocytes to the cancer cells. Our selection of primary tumors for the
initial biomarker discovery made sure that the data mainly came from tumor cells than
stromal cells. Our in vitro studies focused on how changes in FABP4 expression in
cancer cells affects their metastatic potential. In our in vivo studies as well, we utilized
DOPC nanoliposomes which are known to be specifically uptaken by cancer cell. Thus
inhibition of tumor progression can be attributed to the inhibition of FABP4 in cancer
cells than stromal cells. Further, we used DESI-MS imaging technique to study the
metabolic changes associated with FABP4 and we extracted data specifically from
cancer cell compartment of the tumor tissues. None of the previous studies used such
sophisticated techniques to delineate the spatial information about the functions of
FABP4. We here present evidences that FABP4 specifically present in cancer cells
can regulate multiple proteins and metabolites to increase infiltrative behavior and
metastatic potential of cancer cells. We thus show that FABP4 present in cancer cells
is responsible for residual disease while stromal FABP4 might play a secondary role
in this pathway.
DESI-MS imaging showed that lipidomic profiles of R0 and RD patients differ
significantly. Mice data also revealed that FABP4 manipulation had significant effects
on the metabolites present in cancer cells. Higher unsaturation and oxidation of fatty
acids and lysophospholipids were observed in higher relative abundance in samples
with high FABP4 expression. Studies have suggested that unsaturated fatty acids can
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activate the beta catenin pathway, downregulate PTEN or increase cancer cell
adhesion and thus play a key role in pathways leading to tumor progression by [128130]. Fatty acid oxidation has been linked with increased metastasis in breast and
ovarian cancer models [52, 131].

Lysophospholipids are considered potential

biomarkers for ovarian cancer. They have also been known to increase cancer cell
migration thus helping tumor progression [132, 133]. High expression of FABP4 can
thus regulate various metabolites and protein pathways that can lead to aggressive
disease.
Future directions
Our study has shown FABP4 and ADH1B as promising molecular biomarkers
for prediction of residual disease. However, in order to for these markers to be
included in the clinical settings, the study needs external validation and development
of CLIA (Clinical Laboratory Improvement Amendments)-compliant assay to assess
FABP4 or ADH1B expression. A prospective trial analyzing FABP4 expression prior
to triaging and comparing it with the surgical outcome of patients will be a great step
forward in establishing the specificity and sensitivity of these markers. Our study used
primary ovarian tumor samples to check FABP4 expression and we showed that
expression of FABP4 in omental tissue is drastically different than its levels in ovarian
tissues. A comprehensive study analyzing FABP4 expression in various metastatic
tissues can further indicate whether similar results can be obtained using metastatic
nodules. On a similar note, serum levels of FABP4 and ADH1B can also be compared
between R0 and RD patients. If similar results can be obtained using serum samples,
the non-invasive approach will make the study more applicable in clinics.
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A recent study elucidating the role of stromal cell gene signature in residual
disease biology is of particular interest [134]. It will be interesting and informative to
study the interaction between FABP4 present in cancer cells and these genes present
in stromal cells, and how this interplay might play a role in residual disease
occurrence.
Our DESI-MS data reveal many metabolites relevant for residual disease. The
data thus lay foundation for future studies which can focus in depth on these
metabolites and the pathways they regulate. Understanding the metabolic
determinants of ovarian cancer growth and of leaving residual disease will further
elucidate underlying mechanisms and open avenues for the development of
therapeutic options targeting these moieties.
Therapeutic strategies using siRNA and miRNAs have proven themselves to
be attractive treatment options for a variety of diseases. In cancer therapeutics, where
there are several undrggable targets, these miRNA and siRNA based options are of
particular advantage. However, there are challenges in making them clinical feasible.
Mir-34 is one of the very few miRNAs that have entered the clinical trials. Studies of
mir-200, miR-192 and mir-630 have proven the potential of miRNA in cancer
therapeutics [82, 135, 136]. Several siRNAs therapies including EphA2 siRNA, ELK1
siRNA, EZH2 siRNA have been able to inhibit tumor progression [137, 138]. Few
studies have been successful in devising delivery vehicles to carry miRNAs and
siRNAs. The DOPC nanoliposomes used in our study have shown promising results
in many prior preclinical studies [136-139]. The liposomes are currently being tested
in Phase 1 clinical trials for delivery of EphA2 siRNAs (NCT01591356). Our study
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utilizing DOPC nanoliposomes encapsulating FABP4 siRNA and miR-409-3p mimic
thus provides further evidence that siRNA and miRNA based treatment options have
potential as cancer therapeutics, specifically for the management of metastatic
disease.
Significance and translational relevance
Residual disease following primary debulking has been associated with poor
prognosis of cancer patients. Patients with high risk of residual disease should ideally
be treated with neoadjuvant chemotherapy to increase the chances of R0 resection at
interval debulking surgery and avoid unnecessary morbidities associated with
cytoreductive surgeries. In this study, we developed molecular biomarkers that can
predict the likelihood of residual disease in ovarian cancer patients. Use of these
biomarkers can help clinicians in triaging patients to personalized treatment option.
Patients with high expression of FABP4 and ADH1B can be at high risk of residual
disease, hence will be ideal candidates for neoadjuvant chemotherapy instead of
unwarranted aggressive primary surgery. This approach will not only increase overall
survival but can also improve quality of life of ovarian cancer patients.
Little is known about the underlying biology of residual disease. Our study uses
various in vitro and in vivo techniques to investigate the pathways that lead to residual
disease and demonstrates the crucial role FABP4 plays in promoting invasiveness
and infiltration of cancer cells. Moreover, ours is the first study to use in vivo mouse
models to study this clinically observed phenomenon. Since the exact replication of
aggressive cytoreduction and assessment of residual disease is not possible in mice;
we devised a modified version of a clinically validated method to predict the likelihood
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of leaving residual disease in in vivo experiments. We hope that this new modified
scoring systems proves useful in initiating more in vivo experiments to study yet
unknown aspects of residual disease pathophysiology.
We also explore the upstream regulatory mechanisms of FABP4 and identified
hypoxia as a major tumor micro-environmental factor regulating FABP4. We further
show that miR-409-3p directly targets FABP4 and in turn is regulated by hypoxia. We
thus provide several lines of evidence that hypoxia-miR-409-3p-FABP4 is the major
axis regulating residual disease in ovarian cancer. Downstream of FABP4, we
investigated protein and lipid pathways regulated by FABP4. Although studies have
focused on the metabolomics of ovarian cancer [56-58]; they don’t identify specific
tumor compartments where the metabolic changes occur. We thus used DESI-MS
imaging technique to get the spatial information of the metabolites. The use of DESIMS technique was mainly considered in identifying tumor margins in surgical resection
or in disease diagnosis [65]. We successfully applied this technique 1) To identify
cancer cell-specific metabolomics associated with FABP4 expression in ovarian
cancer patients 2) To identify metabolomics changes occurring in the cancer cell
compartment after inhibiting FABP4 expression in vivo. Identifying the exact location
of metabolic changes is crucial, not only in understanding how a gene’s functions
influence and shape the cancer biology but it will also help in future therapeutic
development.
We identify FABP4 and miR-409-3p as promising therapeutic targets in ovarian
cancer and using DOPC nanoliposomes containing targeted siRNA and miRNA
molecules, we establish their importance in inhibiting tumor progression. We also
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tested a clinically approved drug to target FABP4. Tamoxifen has mainly been used
in the treatment of breast cancer[140].Some clinical trials have used tamoxifen for
ovarian cancer treatment, but the results of those trials were mixed[141-143].
However, it is important to note that those patients had advanced stage ovarian cancer
and no specific biomarker was used to select patients who would respond to tamoxifen
treatment. Our preliminary experiments suggest that tamoxifen can suppress
expression and functions of FABP4 and can inhibit tumor progression. Future studies
are essential to establish tamoxifen as a part of ovarian cancer management, but our
study lays the foundation for repurposing tamoxifen, a clinically approved drug for
additional usage and also proposes a biomarker (FABP4) to select patients who will
benefit the most with tamoxifen treatment.
Figure 32 gives a summary of results of our study.
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Figure 32 Summary model
We, thus, provide an important conceptual advance in understanding the
causal biology of residual disease, a molecular biomarker based method to predict the
RD status and new therapeutic avenues for ovarian cancer treatment.
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